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CHAPTER 1: INTRODUCTION 
 
1.1 Background of the Study 
Traditional medicine was formerly suppressed, subjected to ridicule and believed to 
be witchcraft during the period of colonialism and apartheid.1 Today, it is one of the 
leading sources for the development of pharmaceutical products by companies from 
the global North.2 Millions of people around the world depend on traditional 
medicines, traditional treatments, and traditional practitioners as a source of health 
care, and in some places it is the only source of care.3 According to the World Health 
Organization (WHO) about 70 to 80 per cent of the population in developing 
countries depend on traditional medicine for their basic health care needs.4 
Frequently referred to as medical knowledge5 held by indigenous and local 
communities (ILCs), traditional medicine is but one of the vast facets of traditional 
knowledge (TK). Some TK is closely associated to genetic resources (GRs)6 and 
most GRs are sources of traditional medicine. The terms “TK associated with GRs”7 
and “traditional medicine” will be used interchangeably in this study because the 
product of the association between TK and GRs is traditional medicine on which 
patents of inventions may be based or derived from.8 
Drug discovery and development strategies based on or derived from natural 
products and traditional medicines are re-emerging as attractive options for big 
pharmaceutical companies and research institutions.9 To patent an invention based 
on or derived from traditional medicine the applicant must overcome a few obstacles. 
                                                          
1
 Witchcraft Suppression Proclamation 27 of 1933. The Witchcraft Suppression Act 3 of 1957 which applied to 
Namibia then South West Africa as a proclamation by virtue of being a mandate territory administered by 
South Africa see J Dugard The South West Africa/Namibia Dispute: Documents and Scholarly Writings on the 
Controversy Between South Africa and the United Nations (1973) 73. 
2
G M Cragg & D J Newman ‘Natural Products: A Continuing Source of Novel Drug Leads’ Biochim Biophys Acta 
(2013) 2-10. 
3
 WHO Traditional Medicine Strategy: 2014-2023 (2013) 16. 
4
 WHO Fact Sheet No.134: Traditional Medicine (2008). 
5
World Intellectual Property Organization (WIPO) Documenting Traditional Medical Knowledge (2014) 3. 
(WIPO Documenting TMK). 
6
 The definition for GRs is provided under chapter 2 of the study. 
7
 The term ‘TK associated with GRs’, ‘GRs and associated TK’ and ‘TK and associated GRs’ have the same 
meaning in this study. 
8
 The terms TK associated with GRs and traditional medicine will be explained in further detail under chapter 2. 
9
B Patwardhan & R A Mashelka ‘Traditional medicine-inspired approaches to drug discovery: can Ayurveda 
show the way forward?’(2009) 14 (15/16) Drug Discovery Today at 805. 
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First, the novelty and occasionally the inventiveness requirement would normally 
impede the patentability of such invention.10 However, the patent system may confer 
rights over GRs and associated TK that have been altered and such alteration has 
led to the development of a novel and sufficiently inventive product in the sense that 
the new invention constitutes an improvement of the traditional medicine.11 
Second, the defensive legislative approach towards excluding all GRs even 
when isolated or purified including genome or germplasm may lead to exclusion of 
products based on GRs.12 The Namibian government has responded to the 
challenge of protecting TK and GRs by passing the Industrial Property Act 1 of 2012. 
Both TK and GRs enjoy defensive protection in terms of the Industrial Property Act.13 
When applied to TK and GRs defensive protection essentially prevents third parties 
from asserting or acquiring the IPRs over TK or GRs.14 Thus, traditional medicine or 
its derivatives cannot be patented as oppose to positive protection whereby TK 
holders are essentially given rights and legal tools to authorise or prevent use of their 
TK.15  
Consequently, defensive protection of this kind may cause the patent law to fall 
below the international minimum requirements under the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS Agreement), 1994 because it 
excludes certain innovations from being protected by patents.16 The TRIPS 
Agreement provides flexibility for governments, particular those from developing and 
least-developed nations, to adjust the protection granted in order to meet socio-
economic goals of the country.17 It provides for exemptions from patentability,18 
which excludes a subject-matter from protection and result in a non-grant of a 
patent.19 However, the TRIPS Agreement does not exclude GRs in isolated or 
purified form including its genome or germplasm. Therefore, by excluding all forms of 
                                                          
10
 C du Champ d’Anier Integrating Public Health Concerns into Patent Legislation in Developing Countries 
(2000) Geneva: the South Centre. 
11
 P Ebermann Patents as Protection of Traditional Medical Knowledge? (2012)  132. 
12
 S 17(1)(i) of the Industrial Property Act. 
13
 S 12(1)(c) of the Industrial Property Act. 
14
 WIPO IGC Practical Mechanisms for the Defensive Protection of TK and GRs within the Patent System, 
WIPO/GRTKF/IC/5/6.  
15
 G Dutfield Protecting Traditional Knowledge and Folklore (2003) 27. 
16
 Art 27(3) of the TRIPS Agreement. 
17
 World Trade Organization (WTO) Fact Sheet September 2006: TRIPS and Pharmaceutical Patents at 2. 
18
 Art 27(3) of the TRIPS Agreement. 
19
 S F Musungu & S Oh ‘The Use of Flexibilities in Trips by Developing Countries: Can They Promote Access to 
Medicines?’ (2006) South Centre in collaboration with the World Health Organization at 33. 
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GRs may lead to questions about whether Namibia is meeting the TRIPS minimum 
standards. 
Third, the patent system can be used to facilitate biopiracy of TK and 
associated GRs as will be seen in the Hoodia case. It is, therefore, no revelation that 
the World Intellectual Property Organization (WIPO) Intergovernmental Committee 
on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore 
(IGC) found that a momentous number of patent applications are of inventions that 
involve TK in some way.20 However, cases of misappropriation can be overcome by 
incorporating disclosure requirements in patent laws.21 The international community, 
including the IGC, has recognised such requirement as preferable to prevent 
granting ‘erroneous patents’.22 Disclosure of the place of origin and the source of TK 
associated with GRs in patent applications for products based on or derived from 
traditional medicine assist in preventing misappropriation and provide support to a 
compensatory benefit-sharing regime.23  
Finally, the ownership of TK associated with GRs is a general issue. Normally, 
the question is which ILCs constitutes ‘knowledge holders’ for the purpose of benefit 
sharing arrangements, where the use of the TK is widespread and cuts across many 
ILCs may be an issue.24 Nonetheless, as illustrated in the case studies discussed 
below ILCs are willing to share benefits with other knowledge holder communities. 
Moreover, using the patent system for inventions based on or derived from 
traditional medicine can contribute to economic development of a country. TK 
associated with GRs is a highly valuable intangible asset of developing countries.25 
The economic value of this asset could be improved by the use of IPRs particularly 
patents through commercialising inventions based on or derived from traditional 
medicine the manifestation of TK associated with GRs.26 Commercialisation can also 
enable ILCs to actively exploit their TK associated with GRs for their benefit and the 
                                                          
20
 WIPO Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge 
and Folklore (IGC) Recognition Of Traditional Knowledge Within The Patent System (2008) at para 1. 
21
 Ebermann op cit note 11 at 175. 
22
 Art 1 & art 3 of the IGC Document. 
23
 Ebermann op cit note 11 at 175. 
24
 E P Amechi, ‘Using Patents to Protect Traditional Knowledge on the Medicinal Uses of Plants in South Africa’ 
(2015) 11 Law, Environment and Development Journal 51 at 68. 
25
 Amechi op cit note 24 at 64. 
26
 Ibid.  
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benefit of the Namibian economy.27 Thus, it is crucial for developing countries to 
examine the experiences of other developing countries to learn from their policies 
and experience in the field of traditional medicine innovations.28  
Socio-economic development for a country such as Namibia endowed with 
unique GR base is possible particularly since international interest in bio trade with 
and bioprospecting in Namibia has grown in the last two decades.29 This can provide 
a platform where the relationship between TK and the patent system can be used for 
research and development of products based on or derived from TK associated with 
GRs by local and international users.  
However, this relationship between TK and the patent system has rarely been 
to the advantage and benefit of ILCs which have generated and nurtured such TK 
systems in most biodiversity rich developing countries like Namibia.30 In fact, there 
have been recorded instances where bioprospectors have used the patent system to 
facilitate the misappropriation of TK associated with GRs.31 Pharmaceutical 
corporations are heavily criticised for drawing on TK and biological resources and 
filing patent applications for their findings without permission from, or acknowledging 
the ILCs.32 In contrast to the commercial pharmaceutical enterprises’ interest in TK, 
for ILCs, TK is an integral part of the ILCs identity.33 TK is a valuable asset for their 
livelihoods and the ILCs play a crucial role in the sustainable management of GRs 
specifically and biodiversity generally.34 ILCs undoubtedly facilitate the process of 
discovery, development and conservation of medicinal GRs that are used and traded 
globally.35  
The two players, pharma and ILCs operate under national government. The 
interest of a government in TK and associated GRs usually emanates in the form of 
                                                          
27
 C M Correa Protection and Promotion of Traditional Medicine - Implications for Public Health in Developing 
Countries (2002) Geneva: the South Centre at 47. 
28
 J Erstling ‘Using Patents to Protect Traditional Knowledge’ (2009) 15 Texas Wesleyan Law Review 295. 
29
 H Krugmann Namibia’s Thematic Report on the Benefit-Sharing Mechanisms for the Use of Biological 
Resources (2001) 5. 
30
 Amechi op cit note 24 at 58. 
31
 T Beharie & T Shabangu ‘Traditional knowledge, traditional cultural expressions and folklore’ in Owen Dean 
& Alison Dyer (eds) Introduction to Intellectual Property Law (2014) 335. 
32
 D F Robinson Confronting Biopiracy: Challenges, Cases and International Debates (2010) 14.  
33
C Oguamanam International Law and Indigenous Knowledge: Intellectual Property, Plant Biodiversity, and 
Traditional Medicine (2006) at 4. 
34
 K T Kate & S A Laird The Commercial Use of Biodiversity: Access to Genetic Resources and Benefit-sharing 
(1999) 6. 
35
 Ebermann op cit note 11 at 23. 
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rights and obligations arising out of various international, multilateral or regional 
instruments– as well as national imperatives and needs. Consequently, Namibia has 
obligations under the Convention on Biological Diversity, (CBD) 1993, the TRIPS 
Agreement and the Swakopmund Protocol on the Protection of Traditional 
Knowledge and Expressions of Folklore (Swakopmund Protocol or Protocol) as 
well.36 
Consequently, the main concern for ILCs, states and the international 
community is to protect TK and associated GRs from misappropriation by third 
parties aided by the intellectual property (IP) system particularly patent law.37 
Discussions taking place at the IGC has considered a new disclosure requirement 
for all patent application which includes utilization of or is based on or derived from 
TK associated with GRs.38 This disclosure requirement, if implemented correctly, 
may be a means to prevent misappropriation of TK and GRs. 
Hence, the study intends to investigate the relationship between patentable 
traditional medicine inventions and TK associated with GRs. This study argues that 
patentable traditional medicine inventions will not hinder the protection accorded to 
TK associated with GRs in Namibia. In making this determination the study will 
investigate the extent of the protection accorded to TK and GRs in specific 
international and regional instruments and the Namibian Industrial Properties Act 1 
of 2012 and Access to Genetic Resources and Associated Traditional Knowledge 
Draft Bill, 2014.  
The study further argues that patents of inventions using traditional medicine 
can assist in preventing the misappropriation of TK associated with GRs and 
thereby, improve interaction of TK and GRs with patents in order to coexist in 
beneficial manner. To this end, the study will discuss the relevant provisions of 
patent law in aforementioned international, regional and national instruments 
including the system under South African National Environmental Management 
Biodiversity Act 10 of 2004, the Patents Act 57 of 1978 (as amended by the Patents 
                                                          
36
 S 1.1 of the Swakopmund Protocol 2010. 
37
 WIPO Intellectual Property and Genetic Resources, Traditional Knowledge and Traditional Cultural 
Expressions, available at http://www.wipo.int/edocs/pubdocs/en/tk/933/wipo_pub_93.pdf; last accessed on 
10 December 2016. 
38
 Art 3 of the WIPO IGC, Second Revision of the Consolidated Document Relating to Intellectual Property and 
Genetic Resources (2016) (IGC Document). 
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Amendment Act 20 of 2005), and the Protection, Promotion, Development and 
Management of Indigenous Knowledge Systems Bill, 2016. 
 
1.2 Focal research questions 
1. Is patenting of traditional medicine inventions possible through the 
implementation of a disclosure requirement for all patent applications based 
on or derived from TK associated with GRs? 
2. In doing so, will patents of traditional medicine hinder the protection 
accorded to TK associated with GRs? 
 
1.3 Methodology  
Qualitative rather than quantitative type of methodology was used. Literature-based 
relevant publications, legislation, draft bills, books, internet sources, cases, journals 
and WIPO documents were used as guiding tools. Overall a desktop-based 
methodology was used in this study. 
 
1.4 Thesis Structure 
Chapter 1 
This chapter outlined the background to the study, focal research questions, 
methodology, and the thesis structure.  
 
Chapter 2 
Chapter two consists of the conceptual framework of key concepts namely; traditional 
medicine, traditional knowledge associated with genetic resources, bioprospecting, 
biopiracy, access and benefit-sharing, patents, and disclosure requirement. This will 
provide a comprehensive understanding of the main concepts in order to understand 
the manner in which they are used in this study. The chapter will further discuss 
previous instances under which patents were granted for TK associated to GRs i.e. 
the Hoodia plant and Sceletium tortuosum.  
7 
Chapter 3 
This chapter is divided into three parts, namely the international instruments; regional 
instrument; and the IGC text-based negotiations. It serves as the international legal 
basis for the protection of patents, traditional knowledge and genetic resources, and 
is limited to the key instruments which affect Namibia. 
The first part provides an overview of relevant international treaties to which 
Namibia is a signatory. This part of the chapter examines the CBD, the Nagoya 
Protocol and the TRIPS Agreement as the key international instruments that regulate 
the relationship between traditional knowledge associated with genetic resources and 
Intellectual Property generally, and patent law specifically. In addition due to the 
important role indigenous people play in the processing and development of 
traditional medicine it follows that United Nations Declaration on the Rights of 
Indigenous Peoples (UNDRIP) will be discussed. 
Part two of this chapter examines the Swakopmund Protocol on the Protection 
of Traditional Knowledge and Expressions of Folklore within the Framework of the 
African Regional Intellectual Property Organization (ARIPO) to which Namibia is a 
member state. 
Part three looks at the international initiatives lead by the WIPO IGC aimed at 
developing an international agreement for the protection of genetic resources, 
traditional knowledge and traditional cultural expressions. 
 
Chapter 4 
The chapter compares approaches taken for patents of traditional medicine 
inventions and the protection of TK and associated GRs by Namibia in the Industrial 
Property Act 1 of 2012; and the Access to Genetic Resources and Associated 
Traditional Knowledge Draft Bill, 2014, against the approach taken by South Africa in 
the National Environmental Management Biodiversity Act 10 of 2004, the Patents 
Amendment Act 20 of 2005, and the Protection, Promotion, Development and 
Management of Indigenous Knowledge Systems Bill, 2016. The aim of this chapter is 




Chapter five comprises of a conclusion of the study and explores possible legal 
reforms that will lead to sound recommendations for the consideration by the 






















CHAPTER 2: Conceptual Framework 
 
2.1 Introduction 
The focus of the study is the relationship between patents of traditional medicine 
inventions and TK associated with GRs. A topic of this nature is generally difficult as 
it involves different interrelated concepts. The use of terms in this study is very 
specific in terms of how they are defined, thus this chapter provides a 
comprehensive conceptual framework by defining the key terms and concepts 
important for understanding and following the argument of this study. The key 
concepts are specifically traditional medicine, traditional knowledge associated with 
genetic resources, bioprospecting, biopiracy, misappropriation, access and benefit-
sharing, patents, and disclosure requirement. This chapter draws definitions from 
sources such as the CBD, the IGC Document and the Namibian AGR Draft Bill but 
the sources are discussed in chapter three and four in more detail.  
 
2.2 Defining traditional knowledge and ‘traditional knowledge associated 
with genetic resources’ 
Traditional knowledge forms the cultural heritage and intellectual property of ILCs.39 
Despite being the subject matter of many international discussions there is no 
universally accepted definition of traditional knowledge.40 As author Gibson 
eloquently stated ‘[d]efinitional certainty where necessary…must be derived on a 
case by case (or community) basis; indeed, “traditionally”’.41 This is the opposite of a 
universally accepted definition of TK that is potentially constraining to the knowledge 
different ILCs possess the world over.42 Conversely, perhaps the reason why these 
international discussions have been so unsuccessful can be attributed to the lack of 
                                                          
39
 T Greiber et al (eds) ‘An Explanatory Guide to the Nagoya Protocol on Access and Benefit-sharing’ IUCN 
Environmental Policy and Law Paper No. 83 (2012) at 54. 
40
 Examples of this discussions happened under the rubric of WIPO, ARIPO and International Workshop on 
Traditional Knowledge held by the United Nations. 
41
 J Gibson Community Resources: Intellectual Property, International Trade and Protection of Traditional 




one working definition which in turn makes it difficult to advance talks on how to 
protect TK.43 Nonetheless, the WIPO has defined TK as follows: 
Refers to the content or substance of knowledge resulting from intellectual 
activity in a traditional context, and includes the know-how, skills, innovations, 
practices and learning that form part of traditional knowledge systems, and 
knowledge embodying traditional lifestyles of indigenous and local 
communities, or contained in codified knowledge systems passed between 
generations. It is not limited to any specific technical field, and may include 
agricultural, environmental and medicinal knowledge, and knowledge 
associated with genetic resources.44 
The Namibian AGR Draft Bill provisional definition of TK is much shorter: 
Knowledge, practices, innovations or technologies created or developed over 
generations by local communities on the conservation and utilization of 
genetic resources.45 
It is clear from both definitions that TK encompass GRs but only after the adoption of 
the CBD in 199346 were the terms TK and GRs formerly interrelated.47 The CBD as 
the international framework for the conservation and sustainable use of biological 
diversity recognised that ILCs are central to the protection and promotion of in situ 
conservation of biodiversity and its sustainable development.48 TK is not defined 
under the CBD but GRs are defined to mean ‘genetic material of actual or potential 
value’.49 The Namibian AGR Draft Bill takes a step further and defines GRs as: 
any material of plant, animal, microbial or other origin containing or derived 
from functional units of heredity and which has actual or potential value within 
or outside Namibia; all biological resources are genetic resources.50 
                                                          
43
 C B Graber & M A Girsberger ‘Traditional Knowledge at the International Level: Current Approaches and 
Proposals for a Bigger Picture That Includes Cultural Diversity’ in J.Schmid & Hansjörg Seiler (eds) Recht des 
ländlichen Raums (2006) 23. 
44
 WIPO IGC, Glossary of Key Terms Related to Intellectual Property and Genetic Resources, Traditional 
Knowledge and Traditional Cultural Expressions, (2011) (WIPO IGC, Glossary).  
45
 S 1 of AGR Draft Bill of 2014. 
46
 CBD ‘History of the Convention’ available at https://www.cbd.int/history/ last accessed 21 September 2016. 
CBD is discussed in more detail under chapter 3 part 1. 
47
 Art 8(j) of the CBD. 
48
 T Bubela & E R Gold ‘Introduction’ in T Bubela & E R Gold (eds) Genetic Resources and Traditional 
Knowledge: Case Studies and Conflicting Interest (2012) 8. 
49
 Art 2 of the CBD. 
50
 S 1 of AGR Draft Bill.  
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It is seemingly because of the GRs value that art 15 requires member states to the 
CBD to provide access to GRs whilst respecting and preserving TK in terms of art 
8(j).51 
The text of the Nagoya Protocol is of particular importance to this discussion 
because it expressly recognised the interrelationship between TK and GRs and 
applies to TK associated with GRs and GRs as covered by the CBD.52 It is also the 
first time the phrase ‘TK associated with GRs’ was incorporated into an international 
instrument. The Nagoya protocol unfortunately failed to take advantage of the 
opportunity to define and thereby clarify any uncertainties around what TK associated 
with GRs actually encapsulates. However, the WIPO IGC has increased text-based 
negotiations on TK associated with GRs53 and according to the Second Revision of 
the Consolidated Document Relating to Intellectual Property and Genetic Resources 
released on 3 June 2016 (the Document)54 there are two options of a possible 
definition for TK associated with GRs. They are the following: 
 
Option 1: “Traditional knowledge associated with genetic resources” means 
knowledge which is dynamic and evolving, generated in a traditional context, 
collectively preserved and transmitted from generation to generation including but is 
not limited to know-how, skills, innovations, practices and learning, [that subsist in] 
[that are associated with] genetic resources.] 
 
Option 2: “Traditional knowledge associated with genetic resources” means 
substantive knowledge of the properties and uses of genetic resources [and their 
derivatives] held by [rightful holders, including] indigenous [people[s]] and local 
communities [and which directly leads to a claimed [invention] [intellectual property]] 
[and where, but for the traditional knowledge, the invention would not have been 
made].] 
Figure 1 WIPO IGC definitions of TK 
                                                          
51
 Art 8(j) of the CBD is discussed under chapter 3. 
52
 Nagoya Protocol. 
53
 WIPO General Assembly, Twenty-Sixth WIPO General Assembly: Report, WO/GA/26/10 (2000) 71 [WIPO, ’26 
GA report’].  
54
 IGC Document op cit note 37.  
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It is apparent from these two options that there are different views on the subject 
matter. Option 1 is broader in scope regarding the nature of the knowledge, how it is 
developed, what forms of activity it may include, and it is open-ended because of the 
use of ‘including but is not limited to’. On the other hand, it seems that option 2 is 
narrower and more specific.  It is particular about the type of knowledge, who the 
right holders of such knowledge are by referring specifically to ILCs and finally draws 
a direct link between such knowledge and any intellectual property that may arise 
from such knowledge. This definition says that the TK associated with GRs is an 
indispensable condition to an invention, the causa sine qua non.  
Option 1 carries the spirit of TK in that it recognises fundamental characteristics 
of TK namely; (i) dynamic, varied and ever changing nature of TK; (ii) aspects of how 
it is developed and preserved; (iii) passing it on from one generation to the next. 
However, it is not clear on who creates this knowledge, which is arguably the most 
important characteristic of TK. Conversely, option 2 isolates protection of TK 
associated with GRs to instances where it leads to intellectual property. This could 
have an undermining effect on the objectives of the CBD and the Nagoya Protocol to 
protect genetic resources regardless of its association to TK.55 It could also be 
contrary to the boundaries placed by the IGC’s on any developments arising out of its 
text-based negotiations which must be ‘without prejudice to the work pursued in other 
fora’.56  
The challenge for the IGC to define and have a meaningful international 
consensus about the protection of TK associated with GRs can be traced back to 
diplomatic side-steps made during the negotiations of the Nagoya protocol.57 The 
Nagoya protocol left a few unresolved questions: ‘(i) [W]hat is the subject matter for 
TK protection associated with GRs? (ii) how is the protection to be afforded? and (iii) 
how will protection be enforced (particularly in patent applications)?’58 These 
questions will be considered under chapter 3 part 3 of this thesis.  To sum up, there 
is a real challenge to define TK and there is no set definition, however, for purposes 
of this discussion option 2 of the IGC Document is appropriate as it defines TK 
associated with GRs in relation to IPRs which is essential for the study. 
                                                          
55
 The preamble provisions of the CBD and the Nagoya Protocol. 
56
 WIPO, Thirty-Eighth WIPO Assembly: Report, WO/GA/38/20 (Geneva: 2009) 217 [WIPO, ’38 GA report’]. 
57




2.3 Traditional medicine 
As noted above traditional medicine is a product developed over many generations 
by the ILCs with a long history.59 Worth noting is that the term ‘traditional medicine’ 
not only refers to products of GRs but also include traditional medical practices.60 
These practices are interpretations of how ILCs perceive diseases, illnesses and 
health in general.61 Traditional medicine is thus an umbrella term for various things. 
The WIPO is silent on defining traditional medicine but it have quoted the definition 
provided by the WHO directly in the past.62 The WHO defined traditional medicine as 
a:  
Sum total of the knowledge, skill, and practices based on the theories, beliefs, 
and experiences indigenous to different cultures, whether explicable or not, 
used in the maintenance of health as well as in the prevention, diagnosis, 
improvement or treatment of physical and mental illness.63 
“Traditional” in this context does not mean old or untechnical. It is simply an 
expression of ILCs cultures and the way such communities have developed, 
preserved and transmitted the knowledge.64 In industrialised countries adaptations of 
traditional medicine are called complementary or alternative medicine (CAM). The 
terms are interchangeable and are defined as follows: 
The terms “complementary medicine” or “alternative medicine” refer to a broad 
set of health care practices that are not part of that country’s own tradition or 
conventional medicine and are not fully integrated into the dominant health-
care system. They are used interchangeably with traditional medicine in some 
countries.65 
A common example of CAM is acupuncture, a known traditional Chinese medicinal 
treatment.66 CAM systems are characterized by a holistic and highly individualized 
approach to patient care, an emphasis on maximizing the body’s inherent healing 
ability, involving patients as active participants in their own care, addressing physical, 
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mental and spiritual attributes of a disease, and placing a strong emphasis on 
preventative medicine.67 In contrast, traditional medicine varies between 
geographical regions and the practices are more diverse.68 Traditional medicine 
practices are governed by ILCs and as such cultural association is stronger. 
Traditional medicine inspires trust about its safety and efficacy when it is used in 
clinical settings.69 Nonetheless both traditional medicine and CAM have been 
recognised by the WHO to ‘[have] many positive features, and that traditional 
medicine and its practitioners play an important role in treating chronic illnesses, and 
improving the quality of life of those suffering from minor illness or from certain 
incurable diseases’.70 
The use of traditional medicine in this study refers to knowledge that led to the 
development of medicine from GRs by ILCs, which they use to treat, diagnose or 
prevent illnesses.  
 
2.4 Bioprospecting, biopiracy and misappropriation 
Bioprospecting is a form of access to genetic resources. According Beharie and 
Shabangu the term bioprospecting is ‘the process of searching for new potentially 
valuable products when such products are based on biological resources and 
traditional knowledge, and then of commercialising such new products. This includes 
research on, or developments or applications of, indigenous biological resources for 
commercialisation or industrial exploitation’.71 Bioprospectors of TK associated with 
GRs usually include research institutes, universities, ex-situ collections, and 
pharmaceutical, biotechnology and botanical private companies.72  
The Namibia AGR Draft Bill makes a distinction between bioprospecting and the 
commercial phase of bioprospecting project. Bioprospecting is defined to mean ‘an 
exploratory activity that aims to identify genetic resource components and information 
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on associated traditional knowledge’.73 Whereas, “commercialisation phase” of 
bioprospecting project means ‘any research on, or development or application of, 
indigenous biological resources where the nature and extent of any actual or 
potential commercial or industrial exploitation in relation to the project is sufficiently 
established to begin the process of commercialization’.74 
Advocates of ILCs as users of GRs have challenged the legitimacy of 
bioprospecting projects which have in many instances involved participation of ILCs 
who share their TK but end up not receiving compensation for their contribution or at 
least, acknowledgement.75 This type of activity is known as biopiracy.76 Biopiracy has 
been described as the ‘situation where traditional knowledge originating from 
indigenous people is used by others for profit, without permission from, and with little 
or no recognition of, the indigenous people’.77 Southern African ILCs are familiar with 
episodes of biopiracy where bioprospectors have used TK associated with GRs and 
then patent their findings without recognising or sharing benefits with ILCs.78 
Additionally, misappropriation is an act of acquiring and appropriating TK and 
GRs by unfair means79 i.e. in violation of domestic ABS legislation requiring PIC and 
MAT.80 Biopiracy is a form of misappropriation.81 The IGC Document provides two 
possible definitions for misappropriation.82 They are the following: 
 
Option 1: “Misappropriation” is the [acquisition] [utilization] of genetic resources, [their 
derivatives] [and] [or] [traditional knowledge associated with genetic resources] 
without the [free] [prior informed] consent of [those who are authorized to give [such] 
consent] [competent authority] to such [acquisition] [utilization], [in accordance with 
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national legislation] [of the country of origin or providing country].] 
 
Option 2: “Misappropriation” is the use of genetic resources, [their derivatives] and/or 
[traditional knowledge associated with genetic resources] of another where the 
genetic resources or traditional knowledge has been acquired by the user from the 
holder through improper means or a breach of confidence which results in a violation 
of national law in a provider country. Use of genetic resources, [their derivatives] and 
[traditional knowledge associated with genetic resources] that has been acquired by 
lawful means, such as reading publications, purchase, independent discovery, 
reverse engineering and inadvertent disclosure resulting from the holders of genetic 
resources, [their derivatives] and [traditional knowledge associated with genetic 
resources] failure to take reasonable protective measures, is not misappropriation.] 
Figure 2 WIPO IGC definitions of Misappropriation 
The definition of misappropriation provided under option 1 is simpler. It further 
provides specific requirements for the use of TK associated with GRs to be lawful, 
namely: obtain prior informed consent (PIC) from right holders and/or competent 
authority and disclose source and country of origin, which must be met for the use. 
However, option 2 is broader in scope and refers specifically to what an act of 
misappropriation would be, namely: breach of contract and violation of national law. 
What is mean by ‘improper means’ is not clear from the definition but one can deduce 
that it can be any act that is in violation of any statute or regulation in place to protect 
TK associated with GRs from misappropriation. Option 2 laudably includes what 
lawful use or acquisition of TK associated with GRs and its derivatives are and 
provides a list of lawful means to acquire TK associated with GRs. This, however, 
creates a positive obligation on right holders to provide ‘reasonable protection 
measures’. This provision may introduce practical challenges for ILCs. 
It is my view that a combination of option 1 and the first portion of option 2 
where misappropriation is defined can result in a sound final definition. Furthermore, 
the use of the term misappropriation in this study means the use of TK associated 
with GRs or its derivatives without PIC, disclosing of the country of origin or providing 
country or an access and benefit-sharing agreement.  
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2.5 Access and benefit-sharing 
In response to increasing interest in the actual and potential wealth of in situ GRs, 
access to GRs and the fair and equitable sharing of the benefits arising out of their 
utilisation was introduced as the third objective of the CBD.83 ABS is a complex 
concept and in order to provide adequate understanding of the concept one has to 
divide it into two parts, (i) access and (ii) benefits. 
i. Access 
There is no definition of access to GRs in the CBD nor the Nagoya Protocol 
but Namibia has provided a definition for access to GRs in the AGR Draft Bill. 
It is worthy to note that the AGR Draft Bill makes a distinction between access 
to GRs and access to TK. Access to GRs to means: 
[T]he acquisition of samples of genetic resource components for the purpose 
of scientific research, technological development, or bioprospecting, with a 
view to their industrial or other applications, including through the application 
of biotechnology.84 
Whereas access to traditional knowledge means: 
[T]he acquisition of traditional knowledge for the utilization thereof in research 
or development of genetic resources.85 
Article 15(1) of the CBD recognises that governments have the authority to regulate 
physical access to GRs within their jurisdictions.86 It is important, however, to note 
that the CBD does not vest ownership over those GRs in the State.87 Ownership over 
GRs is left to be decided by national laws which include both common law and 
customary law.88 Article 15(2) of the CBD further requires Member States to provide 
favourable conditions in the endeavour of providing access to GRs:89  
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[T]o facilitate access to genetic resources for environmentally sound uses by 
other Contracting Parties and not to impose restrictions that run counter to the 
objectives of this Convention.90 
This sub-article grants discretionary powers to States to decide what ‘environmentally 
sound uses’ are but it is safe to assume that States are required to provide the 
support necessary for potential users to access GRs.91 It is understood that the ‘logic 
behind art 15(2) of the CBD is that fair and equitable sharing of benefits can only be 
realized after access to genetic resources has actually been granted’. 92Access is not 
allowed to all GRs in terms of art 15(3) of the CBD which states that: 
For the purpose of this Convention, the genetic resources being provided by a 
Contracting Party, as referred to in this Article and Articles 16 and 19, are only 
those that are provided by Contracting Parties that are countries of origin of 
such resources or by the Parties that have acquired the genetic resources in 
accordance with this Convention’. 
Two categories of GRs emerge from this article, GRs from ‘countries of origin’ and 
GRs ‘acquired the genetic resources in accordance’ with the CBD, which will entitle a 
provider (the State) of GRs to benefit under the CBD.93 Access to either GRs can 
only be granted subject to the PIC94 of a State providing the GRs, unless otherwise 
determined by that State under art 15(5) of the CBD. This access will only be granted 
on ‘mutually agreed terms’ (MAT)95 between the provider and the potential users.96 
The use of MAT by the CBD suggests that negotiations take place between the 
provider and the potential user. The MAT are to be negotiated on a case-by-case 
basis.97 
According to An Explanatory Guide to the Nagoya Protocol PIC and MAT are 
means of enabling States to ‘authorize access to genetic resources; control their 
subsequent use; and establish the fair and equitable sharing of benefits from their 
subsequent use’.98 PIC simply means potential users should inform those (State or 
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ILCs) that will be affected and those authorised to make decisions prior to accessing 
GRs in order for them to make an informed decision.99 The Guide further explains 
the concept of PIC within the context of ABS which entails the following:  
i. ‘[T]he provider who makes the genetic resources available gives his/her 
consent through an affirmative act;  
ii. this decision (affirmative act/consent) is based on information provided by 
the potential user of the genetic resources; and  
iii.  the information is provided prior to the actual decision (affirmative 
act/consent) that grants access’.100 
However, it remains the prerogative of the State to decide whether or not to have a 
PIC system in place because art 15(5) of the CBD states ‘unless otherwise 
determined by that [S]tate’.101 This provision reiterates the sovereign rights of States 
over GRs as recognised under art 15(1) of the CBD. This does not mean States are 
exempted from the obligation to allow access to GRs.102   
The use of the term “access” to TK associated with GRs is essentially a 
marriage between PIC and MAT which must be ordained by the State and ILCs the 
result of which must lead to benefits. A bioprospector who requires access to GRs 
and TK must meet the aforementioned requirements to obtain such access. Access 
contrary to PIC and MAT is illegal and could lead to misappropriation. 
 
ii. Benefit 
The Namibian AGR Draft Bill defines benefits as ‘arising from the economic use of 
the product or process developed from genetic resources or from associated 
traditional knowledge’.103 The CBD does not define benefits but it is clear from the 
wording of art 15 (7) that there are easily identifiable benefits that Member States can 
regulate through legislature, administrative or policy measures. The object of such 
measures is to share in a fair and equitable manner the benefits arising from access 
to GRs.104  
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There are numerous forms of benefits. Benefits such as R&D results;105 commercial 
or other benefits derived from utilising the GRs provided;106 access to and transfer of 
technology using the GRs;107 participation in all types of scientific research based on 
the GRs;108 participation in biotechnological research activities based on the GRS;109 
priority access to the results and benefits arising from biotechnological use of the 
GRs.110 These benefits must all be part of MATs.111 The inclusion of benefits in MATs 
bounds the user to compensate the provider for allowing access to GRs and 
associated TK. 
 
2.6 Patentable traditional medicine inventions 
The law of patents is a statutory regulated system which provides protection for 
inventions as opposed to discoveries.112 These inventions must further meet the 
requirements of novelty (new); involve an inventive step (non-obvious) and be 
industrially applicable.113 The patentee is granted a monopoly right to prevent others 
from exploiting his or her invention for a fixed period of time.114 In return the patentee 
is required to fully disclose the invention to enable third parties to exploit the 
invention once the protection period has lapse. A patent is territorial in nature in that 
patent protection will only apply in the country where the patent was applied for and 
granted.115 This means a patentee needs protection in other territories; he or she will 
need to file patent applications in the chosen territories.116  
Due to its inherent characteristics traditional medicine may encounter problems 
meeting the patent requirements, mainly because the threshold for the requirements 
of novelty and non-obviousness are not easily met.117 The concept of novelty simply 
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determines that the state of the art invalidates a patent in that all subject matter made 
available in public forms part of the state of the art and therefore, it prevents patents 
to be granted for inventions that already exist.118 On the other hand, the requirement 
of non-obviousness examines whether the invention is obvious to a person skilled in 
the art, if the answer is in the affirmative the invention is not patentable.119 The last 
requirement of industrial applicability is straightforward in that the invention must be 
able to be used or applied in trade or industry.120 
The test for novelty and non-obviousness is discussed in depth in the chapters 
three and four below and how these patent requirements are applied to traditional 
medicine is also discussed below. 
 
2.7 Disclosure requirement 
At the core of the patent system is the disclosure requirement because the grant of a 
patent and the effective use of such rights are anchored on the principle of sufficient 
disclosure.121 Moreover, the disclosure requirement is an integral aspect of any 
relationship that may exist between patents and TK associated with GRs. The 
disclosure requirement is a possible means to prevent misappropriation of TK 
associated with GRs. This is so because it could be used to impose a condition that a 
patent may not be granted involving a traditional medicine invention without also 
disclosing the source of the TK and GRs and the country of origin.122 This is so since 
misappropriation has been defined for purposes of this study to mean the use of TK 
associated with GRs or its derivatives without, inter alia, “disclosing of the country of 
origin or providing country”. Although, the definition of misappropriation does not 
sufficiently include all factors that must be disclosed it still recognises that some form 
of disclosure is necessary to prevent misappropriation.  
Also, it can be a tool to improve ABS agreements, thereby creating a positive 
relationship between patent legislation and legislation regulating access to GRs and 
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associated TK.123 The nature of the disclosure requirement may shape policy 
considerations that may clarify and strengthen this interaction between patents and 
TK associated with GRs. Consequently, it is necessary to define and analyse what 
triggers a disclosure requirement.  
Disclosure requirement is a term used to describe: 
[R]eforms made to patent law at national, regional or international level, which 
would specifically require patent applicants to disclose several categories of 
information concerning TK and/or GRs when these are used in developing the 
invention claimed in the patent application.124 
The IGC identified three broad functions that must be considered for disclosure 
methods relating to TK associated with GRs, specifically: 
i. [T]o disclose any GRs/TK actually used in the course of developing the 
invention (a descriptive or transparency function, pertaining to the GR/TK 
itself and its relationship with the invention); 
ii. to disclose the actual source of the GR/TK (a disclosure of origin function, 
relating to where the GR/TK was obtained) – this may concern the country 
of origin (to clarify under which jurisdiction the source material was 
obtained), or a more specific location (for instance, to ensure that GRs can 
be accessed, so as to ensure the invention can be duplicated or 
reproduced); 
iii. to provide an undertaking or evidence of PIC (a compliance function, 
relating to the legitimacy of the acts of access to GR/TK source material) – 
this may entail showing that GR/TK used in the invention was obtained and 
used in compliance with applicable laws in the country of origin or in 
compliance with the terms of any specific agreement recording the PIC; or 
showing that the act applying for a patent was in itself undertaken in 
accordance with PIC. 
These methods form the basic building blocks to formulate a disclosure requirement 
provision, although it is not intended to be exhaustive nor comprehensive.125 These 
disclosure methods, nonetheless, are intended to set the development and 
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application of the disclosure requirement in a practical and operational manner.126 All 
three disclosure methods are integrated in the IGC Document which provides for a 
mandatory disclosure requirement provision. Article 3 of the Document reads as 
follows: 
Where the [subject matter] [claimed invention] within a [IP Rights] [patent] 
application [includes utilization of] [is directly based on] [is directly based on 
the utilization of] genetic resources [their derivatives] and/or [traditional 
knowledge associated with genetic resources] each Party shall/should require 
applicants to: 
a) Disclose the [providing country that is the country of origin] [country of 
origin [and]] [or [if unknown],] source of the genetic resources, [their 
derivatives] and/or [traditional knowledge associated with genetic 
resources.] 
b) [Provide relevant information, as required by national law, regarding 
compliance with ABS requirements, including PIC, [in particular from 
indigenous [people[s]] and local communities], where appropriate.] 
c)  [If the source and/or [providing country that is the country of origin] 
[country of origin] is not known, a declaration to that effect]. 
It is the opinion of some developed countries that this mandatory disclosure 
requirement would introduce uncertainty into the patent system and would make the 
implementation of benefit-sharing complicated.127 Whereas, most developing 
countries maintain that the disclosure requirement must be mandatory not only for 
patent but also for other IP rights.128 These opposing views were evident when the 
European Union suggested that the obligation to disclose must only be triggered if an 
applicant had actual physical access to the GRs and associated TK that they have 
used subsequently.129 A delegate from Namibia opposed this view and emphasised 
that due to rapid evolution of genetic manipulation and sequencing of genomes 
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physical access to GRs would become unnecessary, thus disclosure must be 
mandatory.130  
Further discussions around the triggers of the disclosure requirement are 
explored further in chapter three under part three of this thesis. Needless to say, the 
current international discussions of the disclosure requirement relating to TK 
associated with GRs are dynamic and fairly complex. Formulating a comprehensive 
legal provision that appreciates the complex nature of the disclosure requirement 
plays a central role in how patents would interact with TK associated with GRs.  
 
2.8 Case studies of patents granted for traditional medicine inventions in 
Southern Africa  
 
Hypothetical scenario 
Cisko Ltd is a pharmaceutical company from the United Kingdom carrying out a 
research project to confirm whether the traditional knowledge that Kanna (Sceletium 
tortuosum) extracts work to treat depression and anxiety. This TK is derived from 
the San community from Southern Africa who have used this plant for decades as a 
mood enhancer giving them a sense of happiness and calmness. It is also used to 
lessen cravings and drug use related withdrawal symptoms. After further studies 
Cisko Ltd develops a new formula that isolates the Kanna extracts and successfully 
applies for a patent for the use of the Kanna extracts and the new formula for 
treating depression and anxiety. 
Figure 3 Hypothetical scenario 
The hypothetical scenario illustrates how bioprospectors acquire TK relating to GRs 
from traditional communities, and how they employ the traditional uses of the GRs in 
their drug R&D. The result of the R&D is patented without any PIC, ABS agreement 
in place or acknowledgement of the relevant ILC. The purpose of this hypothetical is 
to shed light on how patents relating to TK and associated GRs take place in practice 
because this scenario is based on true events. 




In addition, the scenario is used in this study to argue that traditional medicines need 
not be subject to patent applications that are a result of biopiracy. Bioprospectors can 
adhere to national legislative requirements to obtain PIC from the relevant ILC and 
the state, agree on an ABS scheme based on MAT. This will ensure that successful 
leads to biochemical screening for drug discovery carried out by pharmaceutical 
companies and profits made from it can flow back to the ILCs. In doing so, the 
patenting of traditional medicine inventions does not have to stop the protection TK 
associated with GRs enjoys. It also does it inhibit interaction and coexistence of TK 
associated with GRs with patent laws. Below are two case studies under which TK 
associated with GRs has been used in patent inventions. 
 
2.8.1 Hoodia gordonii 
Hoodia gordonii commonly known by the colloquial term ‘!Khoba’ or ‘Ghaap’ is a 
cactus-like plant that grows in Southern Africa including Namibia, South Africa and 
Botswana.131 For centuries the San community used the flesh of the hoodia plant to 
suppress hunger and thirst.132 For medicinal purposes it was consumed to treat 
abdominal pain associated with peptic ulceration.133 The knowledge of the traditional 
uses of the hoodia plant was first published by colonial botanists.134  
A South African-based Council for Scientific and Industrial Research (CSIR) 
discovered that specific extracts of the hoodia plant were active in suppressing 
appetite.135 In 1997, after isolation, synthetisation and development, the CSIR 
patented the use of the plant’s active constituents responsible for suppressing 
appetite.136 This was done without the authorisation and PIC from the San 
community the original holders of the TK associated to the hoodia plant.137  
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In 1998, the CSIR entered into an exclusive licensing agreement with an English 
biopharmaceutical company Phytopharm.138 As exclusive licence holders 
Phytopharm could manufacture and market products derived from the hoodia plant 
and exploit other aspects of the CSIR’s intellectual property rights (IPRs) relating to 
the hoodia plant.139 Phytopharm entered into a further licence and royalty agreement 
with Pfizer, the pharmaceutical giant.140 Pfizer discontinued development of the 
hoodia plant and Phytopharm to enter into an agreement with Unilever.141 In 2008, 
Unilever also pulled out from the agreement and discontinued development of 
‘P57’.142  
From 2001 to 2002, CSIR received heavy criticism for exploiting the San’s TK. 
After which the South African San Council - representing the San communities from 
Namibia, South Africa and Botswana - was mandated by the Working Group of 
Indigenous Minorities in Southern Africa (WIMSA) to enter into negotiations with 
CSIR.143 The negotiation led to one of the first benefit-sharing agreements that would 
give ILCs a 6 per cent share of royalties from successful commercialisation of the 
hoodia plant.144 Consequently, the San Hoodia Benefit Sharing Trust was 
established.145  
By 2006 illegal trade had escalated to high levels ‘from just 25 tons in 2004 to 
more than 60 tons of wet, harvested material per year, sold as ground powder for 
incorporation into non-patented dietary supplements’.146 Vigilant regulation of illegal 
products on the part of the American Herbal Products Association and permit 
systems introduced in South Africa, Namibia and Botswana for harvesting of the 
hoodia plant led to the rapid decrease of the illegal exporting of hoodia products. As, 
a result those involved in growing commercial hoodia on high quantities negotiated 
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another benefit-sharing agreement with the San, based on a levy on processed 
Hoodia.147 
 
2.8.2 Sceletium tortuosum 
Sceletium tortuosum is the subject matter of the hypothetical scenario discussed 
above. The bioprospecting of the sceletium tortuosum plant by foreign 
pharmaceutical companies is not hypothetical. Accordingly, the sceletium tortuosum 
known by the San community as ‘Kanna’ grows in South Africa.148 The San 
community originally held the TK associated with GR but overtime the TK of its mood 
enhancing properties spread to other ILCs such as the Nama community.149 
Sceletium tortuosum has been described as reducing anxiety, causing relaxation and 
mellowness with no cognitive impairment.150 It is also said to be good for stomach 
ailments, relief for jaw pains including pain in general, and treatment for substance 
dependency.151 The Namaqua people from lower parts of Namibia are also known to 
use Kanna in tea to alleviate hunger and for minor pains.152 
A South African-born medical doctor named Nigel Gericke used the TK 
associated with GR with the assistance of Nama-speaking traditional healers from 
Nourivier and Paulshoek villages in the Northern Cape.153 Dr Gericke established 
HGH Pharmaceuticals in Johannesburg.154 Ever since then, HGH Pharmaceuticals 
acquired seven patents, including a patent in the United States of America, and 
registered two trademarks, namely Zembrim and Eletium, while using the San logo 
on their products.155 HGH Pharmaceuticals is currently the only legal permit holder 
issued in terms of NEMBA and Bio-Prospecting, Access and Benefit Sharing 
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regulations to research, export and commercialise the proprietary sceletium 
tortuosum extract Zembrin.156 The patent for Zembrin extract of the sceletium 
tortuosum is ‘for the treatment of depression, anxiety, alcohol and drug dependence, 
bulimia nervosa and obsessive-compulsive disorder’.157 
The use of Zembrin is the same or similar to the traditional uses of sceletium 
tortuosum, thus HGH Pharmaceuticals acknowledged the San community as ‘the 
“primary knowledge holders” of the TK’, and resulting in an ABS agreement between 
the HGH Pharmaceuticals and the South African San Council.158 The San 
community further acknowledged the Paulshoek and Nourivier Community as 
second beneficiaries.159 Subsequently the Council also entered into an ABS 
agreement with the Paulshoek and Nourivier Community.160 The benefits will be a 
fixed value for three years, which consist of 6 per cent of net proceeds including a 
percentage for the use of the San logo as a trademark by HGH Pharmaceuticals.161 
Thus, 50 per cent of the royalties received by the San community will be paid to the 
Paulshoek and Nourivier Community.162 In 2008, an advance has been paid out 
annually in lieu of royalties.163 Zembrin was released in the formal market in 2013 




This chapter has revealed the complexity of concepts and issues that relate to 
patents of traditional medicine inventions and TK associated with GRs. It also 
illustrates the dependency and interrelation of all the concepts discussed above. Of 
particular importance is the role ILCs play in the formation of TK and because of their 
close connection to biodiversity they hold actual and potential knowledge about GRs. 
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Although the definitions of TK associated with GRs are still heavily bracketed from 
the IGC Document and could be changed what remains undeniable is that traditional 
medicine is the product of the connection between ILCs and GRs. The interest of 
bioprospectors in GRs and associated TK is responsible for the creation of concepts 
such as the PIC, MAT and ABS agreements which are measures implemented to 
confront misappropriation of TK and GRs. Misappropriation i.e. biopiracy, of TK 
associated with GRs leading to the patenting of pharmaceutical products derived 
from or based TK associated with GRs is a common occurrence.  
However, as illustrated by the hoodia and sceletium tortuosum case studies 
patenting of drugs or other products derived from these two plants does not 
necessarily lead to negative outcomes. If regulated properly and based on PIC, MAT, 
ABS and the disclosure requirement, patents of traditional medicine inventions can 
lead to real benefits for ILCs and the local economy. The disclosure requirement 
proves important for the elimination of misappropriation. It is also true that traditional 
medicine patent applications may experience some problems with the patentability 
requirements, particularly the novelty and inventive step requirements. However, if, 
for example a pharmaceutical product influenced by traditional medicine is new and 
non-obvious, it can still be patented. 
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CHAPTER 3: INTERNATIONAL AND REGIONAL FRAMEWORK 
 
3.1 Introduction 
This chapter aims to introduce the international and regional framework, which 
regulates the protection of TK associated with GRs in general and Namibia’s efforts 
in particular, in the context of the patenting of traditional medicine inventions. It 
provides the framework for the more detailed analysis of the Namibian system, which 
follows in Chapter 4. To this end, it discusses international standards of patent law, 
TK and GRs, which are relevant to the definitions of key concepts discussed in 
Chapter 2. This chapter further breaks down contentious international discussions 
underway at the IGC surrounding TK and associated GRs and their interaction with 
intellectual property rights, particularly patent rights, in the context of medicinal uses 
of GRs and associated TK and what that means for Namibia. This chapter is divided 
into three parts, namely the international instruments, regional instrument and the 
IGC text-based negotiations. 
 
3.2 Part 1: The current international framework 
3.2.1 The United Nations Declaration on the Rights of Indigenous 
Peoples (UNDRIP) 
The Declaration on the Rights of Indigenous Peoples of 2007165 is wide-ranging but 
contains some articles relevant to TK and its protection. The Declaration recognises 
the right of indigenous peoples ‘to maintain, control, protect and develop’, inter alia, 
TK ‘as well as the manifestations of their sciences, technologies and cultures, 
including human and genetic resources, seeds, medicines, knowledge of the 
properties of fauna and flora…’.166 This is a property-based approach of TK.167 The 
Declaration further articulates the duty of States to ‘consult and cooperate in good 
faith with the indigenous peoples concerned through their own representative 
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institutions in order to obtain their free, prior and informed consent before adopting 
and implementing legislative or administrative measures’ that may affect indigenous 
peoples.168 The States must take positive steps to recognise and protect such 
rights.169 The purpose of this study is to recommend legal reform as far as TK and 
GRs is concerned, thus it is imperative for the Namibian government to take account 
its duty to recognise ILCs rights to TK and actively include them should the 
government decide to change or make any law regarding TK.  
 
3.2.2 The Convention on Biological Diversity, the Bonn Guidelines and 
the Nagoya Protocol 
More specific international framework for the conservation and sustainable use of 
biological resources is the CBD,170 a legally binding international treaty.171 It is 
founded on three objectives: the conservation of biological diversity, sustainable use 
of its components, and the fair and equitable sharing of the benefits arising out of 
using GRs, which should include appropriate access to GRs and appropriate transfer 
of technologies having regard to all rights over those resources, technologies and by 
appropriate funding.172 Namibia became a party to the CBD by ratification in 14 
August 1997 and as such, it is obliged to uphold the three objectives of the CBD.173  
Article 15 of the CBD reaffirms a long-standing international legal principle of 
State sovereignty over biological resources within its territorial boundaries. This right 
rests on the State, which has the duty to develop national legislation to ensure 
access to GRs results in fair and equitable sharing of benefits arising from the 
commercial and other uses of GRs with their ILCs.174 However, PIC and MAT act as 
prerequisites for access to GRs.175 The CBD presumes that access to GRs is 
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granted in exchange for transfer of technologies, rights over resources and 
appropriate funding.176  
Most importantly, the CBD recognises how central ILCs are in the promotion of 
in situ conservation and sustainable development of biodiversity and obliges States, 
as far as possible, to ‘protect and encourage customary use of biological resources 
in accordance with traditional cultural practices that are compatible with conservation 
or sustainable use requirements’.177  
Further, art 8(j) requires States to - subject to national legislation- ‘respect, 
preserve and maintain knowledge, innovations and practices of ILCs embodying 
traditional lifestyles’ which are ‘relevant for the conservation and sustainable use of 
biological diversity’. This is intended to ‘promote their wider application’ subject to the 
‘approval and involvement’ of ILCs.178 The result of these measures is to ‘encourage 
the equitable sharing of the benefits arising from the utilization of such knowledge, 
innovations and practices’.179 
While the CBD entered into force in 1993, earnest operation of these provisions 
above only materialised in 1999.180 The result is the Bonn Guidelines. The purpose 
of the Bonn Guidelines is to assist States in the ABS process,181 with particular 
emphasis on the obligation of potential users to acquire PIC of providers.182 The 
Guidelines identify the basic requirements for MAT, define the main role and 
responsibilities of users and providers, and stress the importance of the involvement 
of all stakeholders.183 
Although, the Bonn Guidelines are a step in the right direction, they are not 
legally binding184 and were not accepted as a final and sufficient guidance.185 This 
led to the Nagoya Protocol, which was adopted in 2010 after years of discussions 
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and negotiations.186 The Nagoya Protocol received all deposits of ratification and 
accession required and entered into force on 12 October 2014.187 Namibia ratified 
the Nagoya Protocol in 15 May 2014.188  
Moreover, art 5 of the Nagoya Protocol echoes the sentiments of article 15 of 
the CBD discussed above. Article 6 of the Nagoya Protocol provides access to GRs, 
however, for purposes of this study art 7 is of particular importance. Article 7 calls on 
States to take measures in accordance with domestic law aimed at ‘ensuring that TK 
associated with GRs…held by ILCs is accessed with the PIC or approval and 
involvement of these ILCs, and that MAT have been established’.189 
The Nagoya Protocol reiterates the relationship between TK and GRs and the 
essential role of ILCs in this relationship. States are also required in terms of art 12 
to take into consideration the customary laws, community protocols and procedures’ 
of ILCs with respect to TK associated to GRS when translating the obligations of the 
Protocol into domestic laws. Some care must be taken by States ‘not to restrict the 
customary usage and exchange of GRs and associated TK within and amongst ILCs 
in accordance with the objectives of the CBD’.190 
More importantly, the Nagoya Protocol further addresses enforcements 
mechanisms in art 12bis which relates to TK and associated GRs, including 
‘situations of non-compliance’ and ‘cooperate in cases of alleged violation of 
domestic ABS legislation or regulatory requirements’.191 The Nagoya Protocol has 
provided significant advances for the protection of TK and associated GRs, albeit the 
subject of TK protection remains unresolved on the international level. 
Like the UNDRIP, the CBD and the Nagoya Protocol reiterate the importance of 
involving ILCs when it comes to access to GRs and associated TK. The CBD and 
more specifically the Nagoya Protocol introduced principles such as PIC, MAT and 
ABS, defined in Chapter 2, as essential factors in protecting TK and GRs, on the one 
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hand and regulating access to them, on the other hand. However, whilst recognising 
the relationship between TK and GRs and access thereto, the Nagoya Protocol 
failed to clarify the instance under which the GRs and associated TK – i.e. traditional 
medicine – is used in an invention subject to a patent application.  
Nonetheless, Namibia’s obligations under the CBD and the Nagoya Protocol 
are reflected in the AGR Draft Bill. It is important to note here that both the CBD and 
the Nagoya Protocol requires that Namibia take legislative measures to protect and 
preserve GRs and TK. However, they also require that such measures must be 
taken to ensure access to GRs and associated TK.192 This shows that protection for 
TK and GRs is not absolute, and that such protection is subject to access based on 
PIC, MAT and the involvement of ILCs.193 This creates a balance between protection 
and access, which is a fundamental aspect of this study’s argument that access and 
use of TK associated with GRs does not stop the protection they enjoy.  
 
3.2.3 The TRIPs Agreement 
The TRIPS Agreement is built on the principles of most-favoured-nation treatment 
and national treatment.194 It further establishes a broad set of minimum international 
standards which is binding on all members of the World Trade Organization 
(WTO).195 TRIPS sets these standards by requiring that the substantive obligations 
under the main conventions of the WIPO such as the Paris Convention for the 
Protection of Industrial Property (Paris Convention) and the Berne Convention for the 
Protection of Literary and Artistic Works (Berne Convention) in their most recent 
versions must be complied with.196 The Paris Convention regulates a number of 
IPRs, namely; patents, trademarks, unfair competition, industrial designs, utility 
models, geographical indications, trade names, to trade secrets within the context of 
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unfair competition, but not copyright.197 Thus, the Paris Convention is relevant to this 
discussion; however, referring to it specifically is unnecessary as provisions specific 
to patents in the Paris Convention were carried over to TRIPS. 
Proponents of TRIPS argued that developing countries who signed on would 
enjoy two kinds of gains. First, there would be incentive for research and 
development and invention from local companies leading to the strengthening of 
potential investment.198 Second, companies and patent holders from developed 
industrialised countries would be more likely to invest in developing countries and/or 
facilitate technological transfer provided they implement stronger IPRs.199 Opponents 
of TRIPS argued that for many sectors IP did not matter much and that TRIPS would 
have no effect.200 
Nonetheless, the TRIPS Agreement mattered significantly for the 
pharmaceutical industry as lobbyists of big pharma from the United States of 
America and Europe played a powerful role in the establishment of TRIPS.201 Since 
the ratification of TRIPS, developing countries have frequently sought amendments. 
In order for patent applications based on or derived from biological resources and TK 
to provide disclosure of the source and country of origin of the biological resources 
and TK, evidence of PIC through appropriate authorities and evidence of fair and 
equitable benefit sharing.202 These are measures aimed at preventing 
misappropriation of TK and represent legally binding defensive protection against 
‘bad patents’.203 The WTO has generally refused such amendments.204 The TRIPS 
Agreement has been described, elsewhere, as having a narrow understanding of TK 
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as it tends to favour the economic interests of developed countries and has little to 
no recognition for the value of preserving TK.205 In direct contrast to the CBD. 
Therefore, it comes as no surprise that there have been divergent views 
between developed and developing countries regarding patent protection.206 
Concerns of the fundamental difference between the developed and developing 
countries led to incorporating a number of flexibilities within the TRIPS Agreement.207 
These include (i) the transition period;208 (ii) compulsory licencing;209 (iii) public and 
non-commercial use of a patent;210 (iv) parallel importation;211 (v) exception to 
patents rights;212 and (vi) exemptions from patentability.213 The TRIPS flexibilities are 
described as essential tools to economic development for developing countries.214 
The exemption from patentability flexibility is of particular importance to this 
discussion and will be expanded on below. 
Exemptions from patentability simply mean that a subject matter is excluded 
from protection which results in an unsuccessful patent application.215 In terms of 
article 27 (1) of TRIPS patent protection must be extended to all inventions without 
discrimination to any field of technology. This article also sets out the criteria of 
novelty, inventive step, and industrial applicability for an invention to be granted 
patent protection. The terms ‘novelty’, ‘inventive step’, and ‘industrial applicability’ 
are not defined under TRIPS and therefore, members of the WTO have the flexibility 
to determine the scope of patentability for inventions.216  
Article 27(3) of the TRIPS Agreement allows countries to exclude from 
patentability ‘diagnostic, therapeutic and surgical methods for the treatment of 
humans or animals’; plants, and animals other than micro-organisms, and essentially 
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biological processes for their production.217 From the definition of biological 
resources in chapter 2, one can deduce that patents of inventions that are based on 
or derived from traditional medicine can be granted provided that they are not 
‘essentially biological processes’. The TRIPS Agreement does not exclude from 
patentability GRs, which is isolated or in a purified form neither does it exclude GRs 
genome or germplasm.  
The TRIPS Agreement identifies enforcement mechanisms in Part III, which 
obliges Members to adopt effective action against any infringement of IPRs covered 
under TRIPS including speedy remedies.218 This enforcement includes civil219, 
administrative220 and criminal procedures and remedies.221 Nonetheless, Members 
can decide on their own legal system.  
 
3.3 Part 2: The current regional instrument 
3.3.1 The Swakopmund Protocol  
The Swakopmund Protocol is an IP instrument tailor made in such a way that legal 
protection fits ‘the specific characteristics’ of TK and TCE. The Swakopmund 
Protocol222 was adopted August 2010, at a Diplomatic Conference in Swakopmund, 
Namibia under the auspices of the African Regional Intellectual Property 
Organisation (ARIPO). The Protocol was signed by nine African states,223 including 
Namibia, and expected to come into force three months after six states have 
deposited their instruments of ratification or accession.224 The main purpose as the 
Protocol expresses is to provide protection for TK holders and custodians against 
infringement and acts of ‘misappropriation, misuse and unlawful exploitation beyond 
their traditional context’.225 The Protocol appreciates the ‘dynamic and evolving 
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nature of TK and the characteristic of TK systems as frameworks of ongoing 
innovation’.226 Laudably the Protocol grants high importance to customary law.227 
This is so especially since TK belongs to the ILCs and as custodians of TK it is fitting 
their laws regulate the system.228 Section 3 of the Protocol provides for the 
establishment of a National Competent Authority directed to implement the 
provisions of the Protocol. Education, advice, regulation and the settlement of 
disputes are amongst the duties of the National Competent Authority – as well as the 
ARIPO office.229  
The Protocol is divided into two sections, namely, Part II on traditional 
knowledge and Part III on expressions of folklore, which are both prefaced by 
“Protection criteria”.230 Automatic protection is granted to TK that meets the following 
criteria in terms of section 4, it must be: 
i. generated, preserved and transmitted in a traditional and intergenerational 
context; 
ii. distinctively associated with a local or traditional community; and 
iii.  integral to the cultural identity of a local or traditional community that is 
recognized as holding the knowledge through a form of custodianship, 
guardianship or collective and cultural ownership or responsibility. 
Customary practices, laws or protocols may establish such a relationship 
formally or informally. 
The protection of TK is not subject to any formalities.231The duration for protection is 
for as long as these criteria are met and 25 years if the TK belongs to an 
individual.232  
In terms of the obligations of Namibia under the Swakopmund Protocol the 
beneficiaries of TK are the holders of that knowledge, i.e. the ILCs and individuals 
within the communities who are involved in the creation, preservation and 
                                                          
226
 Sec 1.3 of the Swakopmund Protocol. 
227
 L Y Ngombe ‘The Protection of Folklore in the Swakopmund Protocol Adopted by the ARIPO’ 2011 The 
Journal of World Intellectual Property 403-411. 
228
 Saima Nghihalwa An Analysis of The Registration of Traditional Product Names, Terms, Symbols and Other 
Cultural Expressions as Trademarks in Namibia (unpublished LLM thesis, University of Cape Town, 2014) 54. 
229
 S 14 of the Swakopmund Protocol. 
230
 O’Hinz M ‘The Swakopmund Protocol on the Protection of Traditional Knowledge and Expressions of 
Folklore’ (2011) 3 Namibia Law Journal 1 at 108. 
231
 S 5 of the Swakopmund Protocol. 
232
 S 13. 
39 
transmission of TK.233 According to s 7, the Protocol grants exclusive rights to ILCs 
to authorise the exploitation of their TK and to prevent exploitation without their PIC. 
The fair and equitable sharing of benefits (including non-monetary benefits) 
generated by the commercial or industrial use of TK will be determined by a mutual 
agreement between parties and in the absence of such mutual agreement, the 
National Competent Authority must act as mediator for the parties to reach an 
agreement.234 Acknowledgement of the right holders is also required for use of TK 
‘beyond its traditional context’.235 
Insofar as GRs is concerned, s 15 explains that authorised access to TK 
associated with GRs does not mean the user has the right to access such GRs.236 
The Protocol thereby recognises the relationship between TK and GRs. However, it 
also means that under the Protocol, bioprospectors may have access to TK that is 
associated with GRs but it does not mean that such bioprospectors can have access 
to the said GRs. Consequently, the Protocol creates no link between it and the CBD. 
This is a major oversight by the regional instrument, which had an opportunity to 
clarify the African position on TK associated with GRs and, how it should relate to 
IPRs. The Protocol does not address IP issues that may arise out of the use of TK 
associated with GRs, which may create practical challenges for a person seeking an 
IPR. This means that Namibia must decide in terms of domestic legislation how TK 
associated with GRs will interact with IP laws. 
 
3.4 Part 3: International discussions and legal alternatives 
3.4.1 The Intergovernmental Committee on Intellectual Property, Genetic 
Resources, Traditional Knowledge and Folklore 
The Intergovernmental Committee on Intellectual Property, Genetic Resources, 
Traditional Knowledge and Folklore (IGC) was established in 2000 by the WIPO.237 
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The main purpose of the IGC is to undertake text-based negotiations in order to 
reach an agreement for an international treaty to ensure the balanced and effective 
protection of, inter alia, GRs and TK.238 The Second Revision of the Consolidated 
Document Relating to Intellectual Property and Genetic Resources (the Document) 
is the latest draft document from the 30th session released 3 June 2016.239 The main 
objective is to prevent misappropriation of GRs and associated TK in the context of 
IPRs particularly the patents systems.240 The revised document was passed on to 
the 34th session of the IGC for discussion, after which it will be deferred to the WIPO 
General Assembly in 2017 in accordance with the committee’s mandate.241 
The Document remains heavily bracketed reflecting the international dissensus 
about the protection of TK associated with GRs. The objectives are the most 
contested provision in the Document. The Document is divided into two main 
proposals. The first proposal of the Document contains three formulations for 
possible objectives in terms of art 1 as a result of disagreement amongst member 
states on whether to include prevention of misappropriation and permitting erroneous 
patents.242 Another cause of objection was the use of ‘erroneous patents’, where it 
was argued that it is not a legal term and should be replaced by reference to the 
patent not meeting the patentability requirements.243 
The subject matter of this Document is clearly GRs, TK and TK associated with 
GRs.244 The alternative subject matter is whether specific inclusion of patent 
applications for inventions directly based on GRs and associated TK should be 
made.245 In my view the specific inclusion of patent application derived from or based 
on TK associated to GRs as part of the subject matter links it to the objective of the 
Document which is to prevent misappropriation through the granting of ‘erroneous 
patents’ and as such should form part of the subject matter.  
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Furthermore, most of the discussion was around the ‘triggers’ of the proposed 
mandatory disclosure requirement for patent applications.246 Developing countries 
supported disclosure if a claimed invention includes utilisation of GRs and TK 
associated with GRs, which they contended ‘to be a clearer and more objective 
standard’.247 Whereas, developed countries found ‘a direct link’ approach between 
the claimed invention and the TK associated with GRs more suitable.248 According to 
this approach the claimed invention must be directly based on GRs and associated 
TK to trigger the disclosure requirement.249 Nonetheless, it is must be noted that 
even though there are differing views on the ‘triggers’ of the disclosure agreement, 
there is at least a sense that the disclosure requirement is important in the 
relationship between patents and TK associated with GRs. As mentioned in chapter 
2, the disclosure requirement is instrumental in preventing improper patents and 
preventing misappropriation of TK associated with GRs. 
In addition, article 4 of the Document provides two alternatives for an exception 
and limitation clause. Alternative 1 requires the adoption of ‘exceptions and 
limitations necessary to protect the public interest’ without unduly prejudicing the 
implementation of this instrument.250 In contrast, alternative 2 provides for instances 
under which disclosure is not necessary such as TK in the public domain, 
commodities, human GRs, and GRs beyond territorial boundaries of a country.251 
Furthermore, the disclosure requirement should not be imposed on patent 
applications filed before the entry into force of this instrument.252 More importantly, 
the Document requires States to provide ‘effective and proportionate legal and 
administrative measures to address non-compliance’.253The provision on sanctions 
and remedies will apply for both ‘pre-grant’ and ‘post-grant’ for a patent invention 
based on or derived from GRs associated with TK.254  
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Interestingly, the second proposal of the Document proposes to completely do away 
with the first proposal, in that no new disclosure requirement must be imposed on 
patent applications provided it meets the patentability criteria.255 The premise of this 
study will be nullified if the IGC decides to incorporate this proposal in the final 
instrument. 
Defensive measures such as databases are also under consideration in terms 
art 6 of the Document. The purpose of such a database would be to assist a patent 
office in examining a patent application for patentability requirements particularly the 
novelty and inventive step requirements, to prevent misappropriation of TK 
associated with GRs.256The Indian Traditional Knowledge Digital Library (TKDL) is a 
model registry for many other countries aiming to adopt such a system.257  
Although, no consensus was reached on major issues discussed above, 
however the IGC has made significant progress in identifying what those issues are 
and provided options for addressing them. Consequently, there is no international 
instrument, which deals specifically with TK associated with GRs and how it relates 
to IPRs and more specifically patent rights. There are currently no international 
obligations for Namibia to deny patents of traditional medicine inventions.  
 
3.5 Conclusion  
At an international level, the debates and issues concerning TK and associated GRs 
are fundamentally challenging as it involves many different stakeholders and many 
international agreements. At the centre of each agreement or negotiation is the issue 
of TK and associated GRs misappropriation aided by the formal IP system, 
particularly the patent system. The CBD provides a broad international legal 
framework regulating access to GRs and benefits arising out of its use but the 
Nagoya Protocol provides specific requirements i.e. PIC, fair and equitable sharing 
of benefits arising from their utilisation based on MAT, for a regulatory framework. 
On the other hand, the TRIPS Agreement is silent on TK. However, patents of 
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traditional medicine inventions may be granted, insofar as it concerns TK associated 
with GRs provided the normal patentability requirements are met. Furthermore, it 
should is not be an excluded subject matter such as ‘essentially biological process’. 
At the regional level, the Swakopmund Protocol conceptualises the sui generis 
protection for TK. It is similar to the Nagoya Protocol in many respects but differs in 
respect of TK associated with GRs because the Swakopmund Protocol does not 
provide an extensive provision, which caters for instances under which such TK 
associated with GRs may become subject to an IP right such as patents. 
Finally, the IGC has explored, inter alia, the misappropriation of TK associated 
with GRs through the granting of improper patents without disclosing whether the 
claimed invention is based on or derived from TK and associated GRs. The 
discussions at the IGC are highly contentious because of opposing views on how to 
protect TK from misappropriation. This chapter also revealed that the international 
community understands that the disclosure requirement is a practical measure 
through which misappropriation of TK and GRs can be prevented. This is so 
regardless of the shape such disclosure requirement would take, which is one of the 
main issues debated before the IGC. Most importantly, no international instrument 
discussed above prohibits the patenting of traditional medicine inventions. It also 
means that Namibia is under no obligation to prohibit inventions based on or derived 
from TK associated with GRs. 
This chapter provided foundation for the domestic legislation subject to the 










CHAPTER 4: A COMPARATIVE STUDY OF THE NAMIBIAN AND 
SOUTH AFRICAN PATENT AND TRADITIONAL 
KNOWLEDGE ASSOCIATED WITH GENETIC 
RESOURCES LEGAL SYSTEMS 
 
4.1 Introduction  
The aim of the study is to investigate whether patenting traditional medicine 
inventions are possible without hindering the protection accorded to TK associated 
with GRs. The instruments discussed under chapter 3 provided the international and 
regional obligations that Namibia must implement through legislation regarding TK 
associated with GRs and patents. This chapter identifies how these obligations have 
been adopted in Namibia and compares the approach taken in the Namibian legal 
system in providing for patents and the protection of TK and associated GRs against 
the approach taken in the South African legal system.  
This is done by providing a brief background into the Namibian and South 
African legal history, which will show why a comparison between two countries is 
appropriate. The chapter is then divided into two sections, each dealing with the 
respective jurisdictions. Section 4.3 deals with Namibia and the separate legislation 
that deals with TK associated with GRs and patents. Whereas section 4.4 deals with 
South Africa and its parallel legislation.  
 
4.2 Background 
The Republic of Namibia previously known as South West Africa (SWA) was 
declared a German Protectorate in 1884.258 However, from 1920 SWA became a 
Mandated Territory of South Africa in terms of the Peace Treaty of Versailles.259 As a 
result, the Namibian judicial and legislative systems were an extension of the South 
African legal system.260 Namibia attained independence in 1990 followed by the 
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promulgation of the Constitution of the Republic of Namibia in the same year.261 The 
Constitution is the supreme law of Namibia and all laws derive legitimacy from the 
Constitution.262 Subsequently, in terms of article 66 (1) of the Constitution all 
common law in force on the date of independence will remain valid to the extent it 
does not conflict with this Constitution or any other statutory law. The parliament is 
vested with the power to repeal or modify any part of the common law, which is 
inconsistent with the Constitution, or any other statutory law.263 Therefore, some 
statutes and regulations that were in force during South Africa’s administration in 
SWA, still remain valid and enforceable in Namibia.  
People from both Namibia and South Africa suffered during Apartheid, a 
political and legal system.264 The effects of apartheid were also evident in the context 
of traditional medicine and traditional healers. Traditional healers and the use of 
traditional medicines have since endured a negative image in Namibia and South 
Africa.265 One of the main contributing factors to this negative association with 
traditional medicine is the role colonial powers played through enactment of 
legislation such as the Witchcraft Suppression Act 3 of 1957 and the Witchcraft 
Suppression Amendment Act, 1970 implemented in South Africa.266 Fortunately, the 
South African Law Reform Commission determined the Witchcraft Suppression Act 
as unconstitutional insofar as harmful witchcraft practices are concerned.267  
As far as Namibia is concerned, the Witchcraft Suppression Proclamation 27 of 
1933 was repealed and the use of traditional medicine was legalised.268 An estimate 
of 2400 traditional medical practitioners in Namibia are registered with the National 
Eagle Traditional Healers Association (NETHA), however, the actual number of 
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practicing traditional healers could be higher.269 More recently, traditional healers 
have been approached by international bioprospectors, local research institutions 
and governments for their traditional medicine.270 This has triggered the formulation 
of national legislation such as the Access to Genetic Resources and Associated 
Traditional Knowledge Draft Bill, 2014 (AGR Draft Bill). This Draft Bill takes on a sui 
generis approach which is intended to align national laws with the obligations of 
Namibia under the Nagoya Protocol.271 The AGR Draft Bill regulates access to GRs 
and associated TK based on principles of PIC, ABS, and MAT.272 The AGR Draft Bill 
makes no express mention of IPRs that may arise from access and use of the GRs 
and associated TK in the sense where it links with the Industrial Property Act. 
However, the Industrial Property Act provides protection for both TK and GRs.273 
Similarly, the South African National Environmental Management Biodiversity 
Act 10 of 2004 (NEMBA) is aimed at, inter alia, redressing the inequalities and 
injustices of the past which excluded rural communities from using natural 
resources.274 This was a result of an exclusionary paradigm developed by the 
colonial government.275 Furthermore, as a signatory of the CBD, South Africa has 
given effect article 8 of the CBD through the enactment of NEMBA.276 To ensure full 
compliance with the CBD on access to GRs, and fair and equitable sharing of 
benefits arising from their use, the Patents Act 57 of 1978 (as amended by the 
Patents Amendment Act 20 of 2005)277 is linked to NEMBA for instances where a 
patent is sought for inventions based or derived from TK and associated GRs in 
South Africa.278 
In 2004, the South African Cabinet further approved a National Indigenous 
Knowledge Systems Policy and in 2013 the Department of Science and Technology 
                                                          
269
A Cheikhyoussef et al ‘Ethnobotanical study of indigenous knowledge on medicinal plant use by traditional 
healers in Oshikoto region, Namibia’ (2011) 7 Journal of Ethnobiology and Ethnomedicine 10. 
270
 M Meincke ‘Negotiating traditional medicine in Namibia: the politics of health and development’ Nordiska 
Afrikainstitutet available at http://www.nai.uu.se/research/finalized_projects/negotiating-traditional-m/ last 
accessed on 22 November 2016. 
271
 S Watanabe  & K N Farrell Challenges of Namibian administrative structure to implement the Access to 
genetic resources and Benefit Sharing legislation (2015)  2.  
272
 Preamble of the AGR Draft Bill. 
273
 S 17(1)(i) & S 12(1)(c) of the Industrial Property Act. 
274
 H A Strydom and N D King (eds) Environmental Management in South Africa 2
nd




 Strydom op cit note 273 at 107. 
277
 Hereinafter referred to as the Patent Act. 
278
 Beharie op cit note 31 at 336. 
47 
(DST) developed a draft Bill for the protection, promotion, development and 
management of Indigenous Knowledge Systems (IKS Bill), which is based on the 
Indigenous Knowledge Systems Policy.279 The DST published a latest draft of the 
IKS Bill on 8 April 2016.280 The IKS Bill like the AGR Draft Bill proposes a sui generis 
system281 for TK including knowledge of GRs.282  
Caution must be taken concerning the Namibian AGR Draft Bill and the South 
African IKS Bill as both are still in the drafting phase and could change in the future. 
This study exclusively deals with the provisions of the latest Bills from Namibia and 
South Africa. Furthermore, it would be appropriate to draw inspiration from the South 
African case law as the Namibian Courts have yet to interpret IP laws, generally and 
patent laws specifically.  
 
4.3 The Namibian legal system 
4.3.1 The Industrial Property Act 1 of 2012 
In terms of s 13 of the Industrial Property Act, patents are available for any invention, 
including products or process, in all fields of technology, provided the invention is 
new, involves an inventive step and is industrially applicable. The term of a Namibian 
patent is 20 years after the filing date of the application for the patent.283 A patent 
granted in Namibia only provides monopoly within Namibia and its territorial waters.  
There are certain matter excluded from patentability and they are listed in the 
statute. The exclusions are listed in s 17 of the Industrial Property Act but for 
purposes of this discussion only one needs mention. In terms of s 17(1)(i) of the 
Industrial Property Act all natural living beings and biological materials even when 
isolated or purified including genome or germplasm are excluded from 
patentability.284 It follows that regardless of whether it is associated with TK, any 
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invention involving GRs cannot be patented. This is a defensive protection of GRs 
from misappropriation.285 The exclusions under s 17 of the Industrial Property Act are 
more expansive then the exemptions provided under art 27(3)(b) of the TRIPS 
Agreement.  
Furthermore, the main argument against patenting traditional medicine is that it 
lacks novelty and in some instances inventiveness as the alleged invention forms 
part of the state of art – otherwise known as prior art.286 In terms of s 14(1) an 
invention is new if it is not anticipated by prior art. Section 12 further defines 
‘anticipated’ to mean forming part of or disclosed by prior art. This includes: 
[K]nowledge developed by or in possession of a local or indigenous community 
and which originated at a date prior to the priority date of the relevant 
invention.287  
Thus, TK forms part of prior art.288 This is known as defensive protection whereby TK 
is protected from misappropriation of it by potential patent applicants.289 
Consequently, during the examination procedure the patent officer will assess 
whether the claims of the invention in the patent application meet the novelty and 
inventive step requirements for patentability by comparing it to the state of the art.290 
A brief explanation of how novelty and inventive step is examined in light of the prior 
art is important to understand how they relate to each other. 
i. Novelty and prior art 
It is a basic concept of Namibian patent law that an invention is new if it is not 
anticipated by prior art immediately prior to the filing date or priority date of a patent 
application.291 Prior art is generally understood to comprise of everything made 
available to the public by means of written or oral description, by use, or in any other 
form on or after the priority date292 but does not include confidential information.293 
The description of “state of the art” in the South African Patent Act is similar to the 
                                                          
285
 This provision has not been subject to previous commentary or interpretation. 
286
 Amechi op cit note 24 at 59. 
287
 S 12(1)(c) of the Industrial Property Act. 
288
 S 12(1) (c). 
289
J  Curci The Protection of Biodiversity and Traditional Knowledge in International Law of Intellectual Property 
(2010) 131. 
290
 Curci op cit note 288 at 210. 
291
 S 12(1) & 14(1) of the Industrial Property Act. 
292
 S 12(1)(a).  
293
 McCauley Corporation Ltd v Brickor Precast (Pty) Ltd 1989 BP 314 (CP) at 335E. 
49 
‘anticipated art’ description in the Industrial Property Act.294 However, s 25(6)-(8) of 
the Patent Act, describes state of the art by creating three categories which mostly 
involve disclosure under namely; (i) ‘all matter made available to the public’, (ii) 
matter forming part of patent applications, and (iii) ‘an invention used secretly and on 
a commercial scale’. State of the art can either be in documentary or oral form, if it is 
documentary, it must be so clear to enable a person skilled in the art to perform the 
invention without extra effort.295 
No Namibian Court has had the opportunity to adjudicate on a patent case and 
in this regard interpretations of patent requirements done by South African Courts 
can be a useful guide. The test for novelty was set out in the Gentiruco A.G. v 
Firestone South Africa (Pty) Ltd case296 related to the claims of the invention. In 
order to establish whether TK has been made available to the public and therefore, 
destroys novelty of an invention (pharmaceutical product) as claimed in the claims, 
the court will apply a three-step test summarised as follows: 
1) the claims of the patent have to be construed; 
2) the piece of prior art (TK) has to be construed; and 
3) the construed claims have to be compared to the piece of prior art.297 
The courts have further clarified the invalidating nature of prior art in Veasey v 
Denver Rock Drill and Machinery Co Ltd298 through the following statement: 
Anticipation destroys the claim to novelty, but the prior publication (or public) 
relied upon as an anticipation must be of the identical – or substantially 
identical – invention claimed…But novelty is not destroyed by prior publication 
or an invention closely resembling that of the patent challenged if the 
difference between the two, however small, is a real difference’.299 
One can therefore argue that patents of pharmaceutical products consisting of 
extracts of traditional medicine that are derived in one way or another from TK 
associated with GRs can be novel provided that there is a difference between them, 
however small. This is more likely because pharmaceutical drugs which consist of 
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active ingredients that do not exist in their pure form in nature are patentable.300 It 
follows that the defensive mechanism for TK and GRs in this instance is not as 
effective because inventions that closely resemble traditional medicine may still be 
patented if there is a real difference. It also means that if the traditional medicine 
invention is patentable, the applicant would have to disclose such TK rendering the 
misappropriation thereof resolved.  
ii. Inventive step and prior art 
In terms of this requirement an invention must be sufficiently different from all other 
previous inventions in such a way that it is not obvious to persons skilled in the art.301 
First, one has to determine the art relating to the patent, second, the person skilled in 
the art, and third, the prior art at the relevant date.302 This includes using the four-
step established in the South African Ensign-Brickford (SA) (Pty) Ltd and Others v 
AECI Explosives & Chemicals Ltd:303 
1. What is the inventive step said to be involved in the patent?304 
In Ausplow (Pty) Ltd v Northpark Trading 3 (Pty) Ltd305 the court with reference 
to the Ensign case held that the claims must be considered to determine the 
inventive step.306 This means the content of the specification are not to be 
considered when determining inventiveness.307 
2. What was the state of the art, at the priority date of the patent, relevant to the step?308 
For this step the state of the art excludes prior co-pending patent applications in 
South Africa and the any secret use on a commercial scale309 In other words, 
all material made available to the public except those mentioned above. 
3. How does the step go beyond, or differ from, that state of the art?310 
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The inventive step is not necessarily a step forward or a big change in the 
existing technology; a small but significant improvement can be considered to 
be inventive.311 
4. Having regard to the further development or difference, would taking the step be 
obvious to the skilled man?312 
The court will require explanation of the aforementioned three steps as primary 
evidence from properly qualified expert witnesses bearing in mind that the court 
has been known to note that expert witnesses views should not supersede the 
judge’s decision-making.313 
There are secondary considerations that are used where the meanings of inventive 
and obvious are unclear.314 Nonetheless, as long as the specific TK and associated 
GRs has not been made available in public and the traditional medicine invention is 
a small yet significant improvement the TK will pass the inventiveness step test. This 
must, however, be the further step in development which is not obvious to the person 
skilled in the art which will be based on evidence given by ‘properly qualified 
witnesses’. 
iii. Capable of industrial application 
The invention must be industrially applicable. The invention must be capable of being 
used or applied in industry, trade or agriculture.315 This is a question of fact and 
seemingly apparent from the invention itself.316 The argument here is that traditional 
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medicine invention is capable of industrial application particularly in the 
pharmaceutical and healthcare industries.  
 
4.3.2 The Access to Genetic Resources and Associated Traditional 
Knowledge Draft Bill, 2014 (AGR Draft Bill) 
The AGR Draft Bill is proposed to regulate access to GRs and associated TK and all 
matters incidental thereto. All rights relating to GRs are vested in the State in terms s 
3(1). This provision is consistent with art 100 of the Namibian Constitution.317 
Whereas, all rights relating to TK associated with GRs is vested in the particular 
ILC.318 First, the AGR Draft Bill319objectives include: the conservation and 
sustainable use of GRs and associated TK for a sustainable life support systems; the 
recognition and protection of the inalienable rights of ILCs to TK; and the facilitation 
of access to GR and associated TK based on PIC, ABS and MAT including effective 
participation of ILCs particularly focused on integrating women in decision-making 
and benefit-sharing.320  
Second, the Draft Bill incorporates notable definitions. ‘Commercialisation’ 
includes filing, obtaining or transferring IPRs in Namibia or abroad.321 ‘Community 
intellectual property rights’ which recognises community rights over TK and 
associated GRs whether registered or not; and ‘community protocols’ that 
incorporate ILCs’ customary law into the framework as procedural norms.322 
Third, in terms of s 4(1) a national authority323 known as the Genetic Resources 
Unit is established falling under the Ministry of the Environment and Tourism. The 
Unit will be led by a Director appointed by the Minister. The Minister through the 
Director is empowered with a wide range of governance powers and duties to 
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regulate access to GRs and associated TK which includes establishing procedures 
for recognition and protection of community IPRs relating to TK and ensuring that 
community IPRs of ILCs are protected.324  
Fourth, ILCs are endowed with the following community rights in terms of s 9(1) of 
the AGR Draft Bill: 
a) the right to collectively benefit from the utilization of genetic resources; 
b) the right to protect their traditional knowledge and technologies associated 
with genetic resources as the traditional custodians and users thereof, and 
in terms of customary law; and 
c) the right to use their traditional knowledge and technologies in the 
conservation and sustainable use of biological diversity; 
d) the right to refuse any access to traditional knowledge or technologies 
associated with a genetic resources where such access would be 
detrimental to the integrity of their natural or cultural heritage, subject to the 
Minister’s right to override this right in the public interest within the 
framework of the Constitution of Namibia. 
Fifth, any person who requires access to GRs and associated TK must apply to the 
Director of the Unit for an access permit.325 This permit can either take the form of an 
academic research permit, a commercial research permit, or a commercial 
exploitation permit.326 Furthermore, exporting of GRs will only be allowed for persons 
who possess an export permit.327 However, a permit will only be granted based upon 
PIC from both the State and the specific ILC involved328 and an access agreement 
has been concluded between the applicant, the State and the ILC.329  
Lastly, benefits shared from access to GRs and TK may take many forms 
including:  
i. money from permit fees;  
ii. royalties; research funding;  
iii. joint ownership of intellectual property;  
iv. employment opportunities;  
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v. contracts to supply the raw GRs;  
vi. access to products and technologies developed from GRs and associate 
TK; institutional and ILC training; and  
vii. providing of equipment, infrastructure and technology support; and any 
other appropriate benefit.330  
Any monies received from access to GRs and associated TK are paid into the 
National Bioprospecting Account in the Environment Investment Fund managed by 
the Unit.331 The funds must be used in the interest of ILCs and for the conservation 
of biological diversity.332 Any person who commits an offence under this Act will be 
liable and punished accordingly.333 It is however, not clear whether the punishment is 
criminal or civil in nature. 
The AGR Draft Bill proposes the right system insofar as the following is 
concerned: first, it recognises the inalienable right of ILCs to TK through bestowing 
upon them community IPRs. Secondly, it highlights the importance of GRs 
conservation and sustainable use by ensuring that access to GRs must be based on 
PIC, MAT, ABS and the effective involvement of ILCs. All of the above are consistent 
with obligations contained in the CBD and the Nagoya Protocol. Thirdly, it notes that 
access to GRs and associated TK can result in its ‘commercialisation’ -including 
obtaining/filing of IPRs - which is important for the advancement of this study’s 
argument in using patents. Fourthly, it establishes an administrative structure – 
Genetic Resource Unit – necessary to regulate access to GRs and all procedures 
incidental thereto, and it also establishes a financial body responsible for receiving 
and sharing monies from access to GRs and associated TK. Lastly, it includes 
sanctions and remedies for non-compliance.  
However, the AGR Draft Bill has failed to address two material aspects 
resulting from access to GRs and associated TK. First, it failed to address how GRs 
and associated TK subject to ‘commercialisation’ (obtaining/filing of IPRs) will relate 
to the existing Industrial Property Act because this Act clearly excludes GRs from 
patentability and includes TK in prior art. Thus, in practice a person who has fulfilled 
all requirements under the AGR Draft Bill who wishes to file a patent application in 
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Namibia involving an invention based on or derived from GRs and associated TK will 
not be able do so. Second, since the AGR Draft recognises that filing for an IPR 
might follow from access, it, however, failed to include a disclosure requirement, 
which is important to prevent misappropriation. 
 
4.4 The South African legal system 
4.3.1 The National Environmental Management Biodiversity Act 10 of 
2004 (NEMBA) 
The main legislation for bioprospecting of TK associated with GRs in South Africa is 
NEMBA334 and the Amendments to the Regulations on Bio-Prospecting, Access and 
Benefit sharing, 2015(Amendment Regulations)335. The NEMBA is based on three 
main objectives, namely: 
i. the management and conservation of South Africa’s biodiversity;  
ii. sustainable use of indigenous biological resources (IBRs); and  
iii. the fair and equitable sharing of benefits arising from bioprospecting 
involving IBRs
.336  
These objectives are acutely similar to the objectives of the CBD discussed above. It 
is important from the onset to state that NEMBA includes provisions which regulate 
cases under which patents are sought for inventions based on or derived from TK 
associated to GRs, otherwise referred to as indigenous biological resources 
(IBRs).337 The regulations apply to commercial or industrial sectors that use TK 
associated to IBRs ‘for biotrade or for research, application or development of drugs 
and complementary medicines’, amongst others.338 The use of TK means ‘traditional 
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use or knowledge’. In terms of reg 1 traditional use or knowledge is defined to 
include:  
customary utilisation or knowledge of indigenous genetic and biological 
resources by an indigenous community or specific individual, in accordance with 
written or unwritten rules, usages, customs or practices traditionally observed, 
accepted and recognised by them, and include discoveries about the relevant 
indigenous genetic and biological resources by that community or individual. 
This definition encapsulates the nature of TK because it understands that TK is 
closely connected with GRs, it can be held by a whole community or by one 
individual and it is not always written.  
Moreover, provisions contained in chapters 6 and 7 of NEMBA are most notable 
as they regulate bioprospecting projects involving IBRs and by extension TK 
associated with GRs. The export of IBRs for purposes of bioprospecting or any other 
kind of research, and provide for a fair and equitable sharing by stakeholders benefits 
arising from bioprospecting involving IBRs.339 
Similar to s 6(2) of the Namibian AGR Draft Bill, s 81(1) of NEMBA prohibits 
bioprospecting involving IBRs carried out by any person without a permit. When 
applying for a permit the applicant must disclose to the issuing authority all 
information pertaining to the proposed bioprospecting activities and the IBRs that will 
be used in such bioprospecting project.340 The permit will only be issued subject to 
certain requirements, particularly;341 the interest of stakeholders including any 
person (organ of state) or community providing access to the IBRs, which should be 
protected by the issuing authority.342 In addition to any ILCs whose traditional use or 
knowledge of the IBRs to which the application relates have initiated or will 
contribute to the proposed bioprospecting.343 Thus, the issuing of the permit will only 
be successful if: 
i. the applicant discloses ‘all material information relating to the relevant 
bioprospecting to the stakeholder and on the basis of that disclosure has 
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obtained the prior consent of the stakeholder for the provision of or access to 
such resources’;344  
ii. the applicant and stakeholders have entered ‘into a material transfer 
agreement regulates the provision of or access to such resources’;345 and  
iii. a benefit-sharing agreement that provides for sharing by the stakeholder in 
any future benefits that may be derived from the relevant bioprospecting.346  
The benefit-sharing agreement the applicant enters into with the stakeholders must 
set out the manner in which, and the extent to which, the IBRs will be used or 
exploited in the bioprospecting project.347 This includes the manner in which and the 
extent to which ILCs will share in the benefits that accrue from the bioprospecting.348 
The benefit-sharing agreement must further specify the following: 
i. the IBRs to which the bioprospecting relates,  
ii. the area or sources from which the IBRs will be collected including the 
quantity of the IBRs to be collected,  
iii. the current traditional uses of the IBRs by the ILCs and any current 
potential uses of the IBRs.349  
This ABS agreement provided by NEMBA includes specific requirements that must 
be fulfilled compared to the ABS agreement provided in terms of the Namibian AGR 
Draft Bill, which only states that there must be an access agreement and provides a 
list of benefits that may accrue from such access.350 
NEMBA goes beyond similar provisions set out in the AGR Draft Bill by 
providing a material transfer agreement. This agreement must prescribe the 
particulars of the supplier, and the exporter or recipient of the IBRs.351 Like the 
benefit-sharing agreement, the material transfer agreement must specify the type of 
IBRs, the area or source from which the IBRs is to be collected, the quantity of the 
IBRs to be collected and the purpose for which such IBRs is exported.352 The 
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Minister must approve both the benefit-sharing agreement and material transfer 
agreement.353 
Moreover, the NEMBA makes a distinction between the discovery phase of a 
bioprospecting project and the commercialisation phase.354 The former phase is 
about using IBRs for commercial research.355 Whereas, the latter phase includes 
biotrade; bioprospecting and integrated biotrade.356 ‘Biotrade’ is a new term 
introduced by the Amendment Regulations that involves ‘buying and selling of milled, 
powdered, dried, sliced or extract of indigenous genetic and biological resources for 
further commercial exploitation’.357 As mentioned above, permits are required for all 
forms of bioprospecting, which should include proof of PIC, signed material transfer 
agreement, a signed benefit-sharing agreement and a non-refundable fee.358  
Lastly, a ‘Bioprospecting Trust Fund’ managed by a Director-general must be 
established into which moneys flowing from benefit-sharing agreements and material 
transfer agreements must be paid.359 Furthermore, all money due to the 
stakeholders (including ILCs) must be paid.360 This financial body is similar to the 
one in the Environment Investment Fund (National Bioprospecting Account) 
established by the AGR Draft Bill.361  
It follows, that NEMBA has ensured that all bioprospecting projects must be 
subject to certain procedures and checks to safeguard TK and IBRs from 
misappropriation. A successful bioprospecting permits depends on full disclosure of 
material information and on agreements that are aimed at benefiting stakeholders 
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4.4.2 The Patents Act 57 of 1978 (as amended by the Patents 
Amendment Act 20 of 2005) (Patents Act) 
It is possible to protect traditional medicine inventions through patents depending on 
the nature and scope of domestic laws.362 The Patents Act requires applicants who 
have lodged a complete patent application in South Africa to state whether or not the 
invention claimed in the application is based on or derived from any IBRs, GRs, or 
from TK and/or traditional use.363 This means an applicant has to lodge a declaration 
or statement on Form P26, which is filed in South Africa on or after 14 December 
2007.364 This statement on Form P26 only relates to South African IBRs, GRs, and 
TK.365 If the invention is based on or derived from IBRs, GRs, or TK the applicant 
must submit to the registrar proof of his/her authority or title to the aforementioned 
resources and knowledge through lodging one of the following: 
i. A copy of the permit issued in terms of NEMBA; 
ii. proof of prior informed consent; 
iii. proof of material transfer agreement; 
iv. proof of a benefit-sharing agreement; 
v. proof of co-ownership of the invention for which protection is claimed; or 
vi. any other proof to the satisfaction of the registrar.366 
The P26 form is a practical tool for keeping track of all patent applications that 
include claims of TK and associated GRs. The P26 form is more consistent with the 
first half of the IGC Document in that patent applications for inventions based on or 
derived from TK associated with GRs is subject to a disclosure requirement.367 
Essentially, the P26 form provides a disclosure system for patent applications 
involving TK associated with GRs. As such, the link between the Patents Act and 
NEMBA is solidified by the ‘commercialisation phase’ of bioprospecting in that a 
patent application may be filed during this time. This also demonstrates that patents 
of traditional medicine can interact and coexist with the rights ILCs over their TK 
associated with GRs.  
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While P26 form is an important part of acquiring a patent for an invention based on 
or derived from TK associated with GRs, the application must still meet all the 
requirements of patentability. Section 25(1) of the Patents Act requires that an 
invention must be novel, involve an inventive step and be industrially applicable. 
Since the patentability requirements were discussed under section 4.3.1 of this 
chapter and all South African case law had been used to advance that discussion, 
here it would simply be a repetition. 
 
4.4.3 Intellectual Property Laws Amendment Act 28 of 2013 (IPLAA) and 
the Protection, Promotion, Development and Management of Indigenous 
Knowledge Systems Bill, 2016 (IKS Bill) 
The Department of Trade and Industry (DTI) drafted the IPLAA. The IPLAA created 
traditional knowledge and traditional cultural expressions (TCE) as a new form of 
IP.368The IPLAA has been criticised as poorly drafted ‘ill-considered attempt at 
protecting TCE’,369 it is, however, irrelevant to TK related to GRs and therefore, will 
not be discussed any further.  
In contrast, many South African IP professionals have applauded the IKS Bill 
‘as a step forward in the right direction’.370 The IKS Bill puts forward a sui generis 
system371 for the protection and commercialisation of indigenous knowledge 
system.372 The IKS Bill establishes National Indigenous Knowledge Systems Office 
(NIKSO)373, and an Advisory Panel to advise NIKSO to carry out the objectives of the 
Bill.374 The Bill further requires registration for protection for IK at a registrations office 
to be established by NIKSO375 and registration of all existing IK must be within 12 
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months of the Act coming into force.376 This placed enormous time pressure to act on 
ILCs.377 
Nonetheless, in terms of s 9(1) all IK, both cultural and functional in nature, 
including medical, agricultural and scientific practices are subject to protection 
provided they meet the eligibility criteria set out in s 11 below: 
a) has been passed on from generation to generation within an indigenous 
community; 
b) has been developed within an indigenous community; and 
c) is associated with the cultural make-up and social identity of that 
indigenous community. 
These requirements are too limiting as it works on the assumption that TK are in fixed 
forms which are historically identifiable or linked to one particular ILC rather than 
understanding that TK may change overtime and may take on different yet related 
forms.378 Nevertheless, the protection for IK lasts as long as it meets the criteria of 
eligibility for protection in terms of section 11,379 after which the IK will be part of the 
public domain.380 The ownership of IK is held by the ILCs and a trustee of the ILC 
holds the IK in trust on behalf of the community. If the holder of the IK cannot be 
identified NIKSO acts as custodian of the IK.381 As holders of the IK ILCs are vested 
with a bundle of exclusive rights under the IKS Bill which includes: a) benefits arising 
from its commercial use; (b) be acknowledged as its source; and (c) restrain any 
unauthorized use of the IK.382 
Furthermore, if potential bioprospectors require access to IK they must apply 
for a licence. 383 The applicant must include, the identity and place of origin of the IK, 
evidence of PIC of the IK holder has been obtained and an ABS arrangement has 
been entered into with the IK holder.384  In other words, this section contains the 
disclosure requirement as proposed in the IGC Document.385 As far as dispute 
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resolution is concerned any person who uses without authorisation or under false 
pretence commits an offence and liable for imprisonment for up to three years or a 
fine of R30 000 or both.386 
Despite being well drafted, the IKS does not provide a link between patents and 
TK associated with GRs. Section 3 set outs the objects of the Bill, however, the s 
3(1)(h) stands out for purposes of this study. Section 3(1)(h) of the Bill reads as 
follows:  
[R]ecognise indigenous knowledge as prior art in the determination of, and 
eligibility for, protection of subject matter under intellectual property laws. 
At present, there is no interpretation of this section. However, this section makes it 
clear that IK is recognised as prior art when it is part of subject matter seeking IP 
protection, thereby providing defensive protection for IK when it is subject to a IPR 
i.e. patent right.387 By doing so, the IKS Bill prohibits patents of inventions based on 
or derived from TK associated with GRs. There is no further indication of a 
relationship between patents and TK associated with GRs in the IKS Bill. It is also 
not clear how the IKS Bill will interact with existing legislation such as the Patents 
Act.388 However, it states in terms of s 32 of the Bill that any rights conferred in 
respect of IP by any statute or common law will trump the provisions of the Bill, in 
practice, and this includes the NEMBA.389 On the one hand, this means that patents 
of traditional medicine inventions can still be granted in terms of the Patents Act and 
NEMBA. On the other hand, it means that although the IKS Bill has made significant 
progress to protect TK defensively, s 32 undermines the creditable work done by the 
DST.390 
Nonetheless, it seems South Africa’s intention is to provide a hybrid system for 
TK. There are two statutes and one bill that regulate protection of TK associated with 
GRs and matters incidental thereto, which means there are potential legislative 
overlaps and duplication of provisions. Whilst NEMBA requires permits to access 
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GRs and associated TK, the IKS Bill proposes a licensing system. This means that 
the departments responsible for governing each legislation must identify and resolve 
the overlaps.391  
 
4.7 Conclusion  
Namibia has complied minimally with international obligations in that the existing 
legislation and the proposed draft bill have given effect to art 8 of the CBD which 
ensures access to GRs. The AGR Draft Bill proposes to provide PIC, MAT and 
benefit-sharing measures for access to and utilisation of TK and associated GRs as 
required under the Nagoya Protocol. Furthermore, access to TK and associated GRs 
will be based on a permit system. The chapter hereby shows that Namibia is on the 
right path in providing the necessary protection for TK associated to GRs from 
misappropriation. 
However, the AGR Draft Bill lacks the disclosure requirement envisaged in the 
IGC Document and when compared to the South African Patents Act and NEMBA. 
Although, the AGR Draft Bill recognises and makes provision for instances under 
which  bioprospectors may file for a patent right arising out of an invention based on 
or derived from TK associated with GRs, it does not clarify how this will be possible in 
relation to the Industrial Property Act. More so since both TK and GRs cannot form 
part of claimed invention and testing whether the invention meets the patentability 
requirements becomes superfluous. Consequently, no patents can be granted for 
inventions based on or derived from TK associated with GRs in Namibia. 
The South African Patents Act and NEMBA demonstrated that it is possible to 
patent traditional medicine inventions. The two Acts collaborated to design a 
disclosure requirement in the form of P26 Form. Proving that a relationship does exist 
between patents and TK associated GRs which works so far.  
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CHAPTER 5: CONCLUSION AND RECOMMENDATIONS 
 
5.1 Conclusion 
The growing importance of TK associated with GRs and the increasing number of 
patents granted for pharmaceutical and biotechnological inventions based on or 
derived from traditional uses of GRs has sparked international debates concerning 
its protection. There have been significant international developments within the 
legal framework that regulates access to GRs and TK and those aimed at protecting 
TK associated with GRs from misappropriation by third parties. However, 
instruments that are in place have not provided sufficient solutions for TK associated 
with GRs which is subject to IPRs. To date work on providing an international 
regulatory framework for TK associated with GRs and IPRs that may be sought for 
access to and use of TK associated with GRs has progressed gradually under the 
ambit of the WIPO IGC.  
The value of traditional medicine to numerous bioprospectors i.e. 
pharmaceutical companies, for R&D of new drugs and other products cannot be 
overstated. Hence, at the centre of the research was the question of whether 
patenting of traditional medicine inventions is possible without encroaching on the 
protection of TK and GRs.  
To this end, the study defined important key concepts that relate to TK 
associated with GRs and patents provided in the relevant international and regional 
instruments. This was done to highlight the specific use of terms in the study. What 
is evident from the discussion of these key concepts was how interrelated they are to 
one another and how important integration of each concept is when patenting of 
inventions based on or derived from TK associated with GRs becomes an issue.  
The illustration of the hoodia case study showed how the plant and its 
traditional uses were misappropriated from the San communities in Southern African 
countries. This means the hoodia plant was subject to R&D and subsequently, to 
numerous patent applications without the authorisation and PIC from the indigenous 
community. However, the sceletium tortuosum case study showed that access to the 
GRs and traditional uses of sceletium that were subject to seven patents was based 
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on PIC of the San community who were identified as the primary knowledge holders 
and an ABS agreement between HGH Pharmaceuticals and the San community. 
Through this the study revealed that patents of traditional medicine inventions need 
not be a result of misappropriation. It was also found that the ongoing discussions at 
the IGC are primarily aimed at addressing the issue of misappropriation of TK and 
GRs which occurs through the granting of improper patents.  
The study concluded that any patent application ensuing from a bioprospecting 
activity must be subjected to a disclosure requirement. The applicant must disclose 
any GRs and associated TK used in the claimed invention; disclose the country of 
origin and the source of the GRs; and provide evidence of PIC and ABS agreement 
as Namibian laws may require. Thus, the disclosure requirement is of such an 
important nature that PIC and ABS agreements are prerequisites to any patent 
application which the claimed invention is based on or derived from TK associated 
with GRs. It augments transparency in the patent system. The disclosure 
requirement will either be triggered by mere use of TK associated with GRs in an 
invention or a direct link between TK associated with GRs and the invention. 
Consequently, the obstacle for patents of traditional medicine, namely 
misappropriation is prevented. It further means that TK associated with GRs 
continues to enjoy protection under the relevant legal framework.  
Furthermore, to determine the parameters of the protection accorded to TK and 
GRs the study explored the international and regional legal framework to which 
Namibia is a member state. The CBD provides general protection for GRs but it 
balances this protection by requiring access to GRs. The study further showed that 
the Nagoya Protocol goes a step further by ensuring that access to TK and 
associated GRs must be based on PIC obtained from ILCs and an ABS agreements 
are reached based on MAT. In addition, the Swakopmund Protocol provides 
comprehensive protection for TK, it, however, failed to clarify what the position on TK 
associated with GRs and how it relates to IPRs. The study found that there is 
currently no international instrument that specifically regulates TK associated with 
GRs. Admittedly, this study attempts to solve an issue that the international 
community has yet to find an answer to. 
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There is currently no law in Namibia that deals specifically with TK associated with 
GRs.392 There is, however, an AGR Draft Bill proposed to regulate access to GRs 
and associated TK in Namibia. The study revealed that the AGR Draft Bill provides 
positive protection to GRs and TK as it endows ILCs with rights to authorise or deny 
access and use of their TK associated with GRs by third parties. It also gives them 
the right to benefit from authorising such access and use of their TK. Nonetheless, 
the Industrial Property Act accords defensive protection to TK and GRs. Defensive 
protection is another obstacle for patenting inventions based on or derived from TK 
associated with GRs as such a patent would be invalid.  
This study further identified patentability requirements as an additional 
obstacle. Patents of traditional medicine must not fall short of the patentability 
requirements as provided under the TRIPS Agreement. The claimed invention 
influenced by traditional medicine must be new, non-obvious and applicable in 
industry. The study in chapter two and four indicated practical challenges patents of 
traditional medicine may face in meeting the requirements of novelty and non –
obviousness. Nonetheless, by illustration of the hoodia and sceletium tortuosum 
case studies, this dissertation concluded that traditional uses and healing properties 
of these two plants resulted in actual patents of pharmaceutical and other products 
which are based on the TK associated to such GRs. This means that traditional 
medicine derived inventions can in certain instances meet the patentability 
requirements.  
Through a comparative analysis of the Namibian and South African legal 
systems, the chapter concluded that a clear relationship must exist between laws 
which regulate patents and TK associated with GRs. In this regard, the South African 
Patents Act and NEMBA are exemplary as the link is clearly represented by Form 
P26. If Namibia amends its patent law to provide positive protection for TK 
associated with GRs then, perhaps, a clear link may exist between the Industrial 
Property Act and the AGR Draft Bill. In which case, South African decisions on 
patent law could be referred to by Namibian courts when a dispute arises. 
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5.2 Recommendations 
In light of the conclusion reached in this study owing from an investigation into the 
relationship between patents of traditional medicine and TK associated with GRs, 
here are number recommendations for the attention of the Namibian legislature and 
the LRDC: 
1. Although defensive protection is aimed at preventing misappropriation of TK 
and GRs, it has been shown in this study that misappropriation can be 
prevented by implementing the disclosure requirement. Thus, section 
12(1)(c) of the Industrial Property Act, 2012 which defines prior art to 
include TK must be amended to exclude TK. In addition section 17(1)(i) of 
the Industrial Property Act, 2012 includes GRs, ‘in whole or in part found in 
nature, even if isolated from it or purified, including the genome or 
germplasm’, under subject-matter excluded from patentability. This sub-
section must be amended by removing ‘even if isolated from it or purified, 
including the genome or germplasm’.  
3. The disclosure requirement is essential to preventing misappropriation and 
creating a link between patents and TK associated with GRs. As such a 
disclosure requirement must be inserted into the Industrial Property Act, 
2012, which must include the requirements of source of the TK and 
associated GRs, country of origin and evidence of PIC and ABS scheme. 
3. The Namibian Access to Genetic Resources and Associated Traditional 
Knowledge Draft Bill, 2014 is not enacted yet thus; it would be prudent to 
revise the Bill so as to create a link between it and the Industrial Property 
Act, 2012.  
4. The Namibian government needs to create awareness for ILCs and 
sensitise them about their rights over TK and empower them to ensure that 
they exercise these rights both locally and internationally. This can be done 
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